ZA200109637B - Conformationally constrained backbone cyclized interleukin-6 antagonists. - Google Patents
Conformationally constrained backbone cyclized interleukin-6 antagonists. Download PDFInfo
- Publication number
- ZA200109637B ZA200109637B ZA200109637A ZA200109637A ZA200109637B ZA 200109637 B ZA200109637 B ZA 200109637B ZA 200109637 A ZA200109637 A ZA 200109637A ZA 200109637 A ZA200109637 A ZA 200109637A ZA 200109637 B ZA200109637 B ZA 200109637B
- Authority
- ZA
- South Africa
- Prior art keywords
- arg
- lys
- phe
- leu
- amide
- Prior art date
Links
- 229940127448 Interleukin-6 Antagonists Drugs 0.000 title description 2
- 108090001005 Interleukin-6 Proteins 0.000 claims description 256
- 102000004889 Interleukin-6 Human genes 0.000 claims description 253
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 159
- 239000005557 antagonist Substances 0.000 claims description 49
- 150000001408 amides Chemical class 0.000 claims description 43
- 150000001413 amino acids Chemical class 0.000 claims description 43
- 230000000694 effects Effects 0.000 claims description 37
- 238000000034 method Methods 0.000 claims description 34
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 26
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 claims description 22
- 206010035226 Plasma cell myeloma Diseases 0.000 claims description 22
- 150000003568 thioethers Chemical class 0.000 claims description 22
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 19
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 18
- 150000007970 thio esters Chemical group 0.000 claims description 18
- 239000002253 acid Substances 0.000 claims description 17
- 208000034578 Multiple myelomas Diseases 0.000 claims description 16
- 125000003158 alcohol group Chemical group 0.000 claims description 16
- 239000000203 mixture Substances 0.000 claims description 15
- 239000008194 pharmaceutical composition Substances 0.000 claims description 15
- 206010028980 Neoplasm Diseases 0.000 claims description 13
- 208000036142 Viral infection Diseases 0.000 claims description 8
- 230000001580 bacterial effect Effects 0.000 claims description 8
- 230000009385 viral infection Effects 0.000 claims description 8
- 208000035143 Bacterial infection Diseases 0.000 claims description 7
- 208000022362 bacterial infectious disease Diseases 0.000 claims description 7
- 125000004122 cyclic group Chemical group 0.000 claims description 7
- 208000023275 Autoimmune disease Diseases 0.000 claims description 6
- 102000010781 Interleukin-6 Receptors Human genes 0.000 claims description 6
- 108010038501 Interleukin-6 Receptors Proteins 0.000 claims description 6
- 208000001132 Osteoporosis Diseases 0.000 claims description 6
- 239000003814 drug Substances 0.000 claims description 6
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 6
- 230000001684 chronic effect Effects 0.000 claims description 5
- 208000035475 disorder Diseases 0.000 claims description 5
- 238000004519 manufacturing process Methods 0.000 claims description 5
- 229910052757 nitrogen Inorganic materials 0.000 claims description 4
- 208000030852 Parasitic disease Diseases 0.000 claims description 3
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 3
- 244000045947 parasite Species 0.000 claims description 3
- 230000036281 parasite infection Effects 0.000 claims description 3
- PQBHGSGQZSOLIR-RYUDHWBXSA-N Arg-Phe Chemical compound NC(N)=NCCC[C@H](N)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 PQBHGSGQZSOLIR-RYUDHWBXSA-N 0.000 claims description 2
- OZILORBBPKKGRI-RYUDHWBXSA-N Phe-Arg Chemical compound NC(N)=NCCC[C@@H](C(O)=O)NC(=O)[C@@H](N)CC1=CC=CC=C1 OZILORBBPKKGRI-RYUDHWBXSA-N 0.000 claims description 2
- 239000003085 diluting agent Substances 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 108010018625 phenylalanylarginine Proteins 0.000 claims description 2
- SENJXOPIZNYLHU-UHFFFAOYSA-N L-leucyl-L-arginine Natural products CC(C)CC(N)C(=O)NC(C(O)=O)CCCN=C(N)N SENJXOPIZNYLHU-UHFFFAOYSA-N 0.000 claims 1
- SENJXOPIZNYLHU-IUCAKERBSA-N Leu-Arg Chemical compound CC(C)C[C@H](N)C(=O)N[C@H](C(O)=O)CCCN=C(N)N SENJXOPIZNYLHU-IUCAKERBSA-N 0.000 claims 1
- 108010000761 leucylarginine Proteins 0.000 claims 1
- 229940100601 interleukin-6 Drugs 0.000 description 233
- 210000004027 cell Anatomy 0.000 description 66
- 102000004196 processed proteins & peptides Human genes 0.000 description 56
- 235000001014 amino acid Nutrition 0.000 description 35
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 28
- 238000003556 assay Methods 0.000 description 25
- 230000002401 inhibitory effect Effects 0.000 description 23
- 230000005764 inhibitory process Effects 0.000 description 23
- 230000008878 coupling Effects 0.000 description 22
- 238000010168 coupling process Methods 0.000 description 22
- 238000005859 coupling reaction Methods 0.000 description 22
- 230000015572 biosynthetic process Effects 0.000 description 21
- 201000010099 disease Diseases 0.000 description 20
- 108010069514 Cyclic Peptides Proteins 0.000 description 19
- 102000001189 Cyclic Peptides Human genes 0.000 description 19
- 102000004127 Cytokines Human genes 0.000 description 19
- 108090000695 Cytokines Proteins 0.000 description 19
- 238000011282 treatment Methods 0.000 description 18
- 238000003786 synthesis reaction Methods 0.000 description 17
- 238000012360 testing method Methods 0.000 description 17
- 206010033645 Pancreatitis Diseases 0.000 description 16
- 238000007363 ring formation reaction Methods 0.000 description 16
- 230000012010 growth Effects 0.000 description 15
- 210000002966 serum Anatomy 0.000 description 14
- 239000000243 solution Substances 0.000 description 14
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 13
- 238000006243 chemical reaction Methods 0.000 description 13
- 239000011347 resin Substances 0.000 description 13
- 229920005989 resin Polymers 0.000 description 13
- 238000012216 screening Methods 0.000 description 13
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 12
- 238000004166 bioassay Methods 0.000 description 12
- 108020003175 receptors Proteins 0.000 description 12
- 102000005962 receptors Human genes 0.000 description 12
- -1 (L)- or (D)- Trp Chemical compound 0.000 description 11
- 206010048998 Acute phase reaction Diseases 0.000 description 11
- 230000003993 interaction Effects 0.000 description 11
- 208000030507 AIDS Diseases 0.000 description 10
- 150000001875 compounds Chemical class 0.000 description 10
- 238000002347 injection Methods 0.000 description 10
- 239000007924 injection Substances 0.000 description 10
- 241000699670 Mus sp. Species 0.000 description 9
- 241000779819 Syncarpia glomulifera Species 0.000 description 9
- 238000004128 high performance liquid chromatography Methods 0.000 description 9
- 238000000338 in vitro Methods 0.000 description 9
- 239000001739 pinus spp. Substances 0.000 description 9
- 235000018102 proteins Nutrition 0.000 description 9
- 108090000623 proteins and genes Proteins 0.000 description 9
- 102000004169 proteins and genes Human genes 0.000 description 9
- 238000000746 purification Methods 0.000 description 9
- DTQVDTLACAAQTR-UHFFFAOYSA-N trifluoroacetic acid Substances OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 9
- 229940036248 turpentine Drugs 0.000 description 9
- 241001529936 Murinae Species 0.000 description 8
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 8
- 230000004658 acute-phase response Effects 0.000 description 8
- 238000004458 analytical method Methods 0.000 description 8
- 238000001727 in vivo Methods 0.000 description 8
- 125000003088 (fluoren-9-ylmethoxy)carbonyl group Chemical group 0.000 description 7
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 7
- 229940124790 IL-6 inhibitor Drugs 0.000 description 7
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 7
- 102000004140 Oncostatin M Human genes 0.000 description 7
- 108090000630 Oncostatin M Proteins 0.000 description 7
- 206010003246 arthritis Diseases 0.000 description 7
- 108010046018 leukocyte inhibitory factor Proteins 0.000 description 7
- 201000001441 melanoma Diseases 0.000 description 7
- 230000003278 mimic effect Effects 0.000 description 7
- 230000001988 toxicity Effects 0.000 description 7
- 231100000419 toxicity Toxicity 0.000 description 7
- 108010062271 Acute-Phase Proteins Proteins 0.000 description 6
- 102000011767 Acute-Phase Proteins Human genes 0.000 description 6
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 6
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 6
- 108010002352 Interleukin-1 Proteins 0.000 description 6
- 102000000589 Interleukin-1 Human genes 0.000 description 6
- 208000007766 Kaposi sarcoma Diseases 0.000 description 6
- 230000030833 cell death Effects 0.000 description 6
- 238000010511 deprotection reaction Methods 0.000 description 6
- 238000011161 development Methods 0.000 description 6
- 230000018109 developmental process Effects 0.000 description 6
- 230000001965 increasing effect Effects 0.000 description 6
- 230000001404 mediated effect Effects 0.000 description 6
- 201000000050 myeloid neoplasm Diseases 0.000 description 6
- 230000001575 pathological effect Effects 0.000 description 6
- 238000002360 preparation method Methods 0.000 description 6
- WBWWGRHZICKQGZ-HZAMXZRMSA-N taurocholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCCS(O)(=O)=O)C)[C@@]2(C)[C@@H](O)C1 WBWWGRHZICKQGZ-HZAMXZRMSA-N 0.000 description 6
- 206010061005 Cardiac myxoma Diseases 0.000 description 5
- 108010005939 Ciliary Neurotrophic Factor Proteins 0.000 description 5
- 102100031614 Ciliary neurotrophic factor Human genes 0.000 description 5
- 208000009386 Experimental Arthritis Diseases 0.000 description 5
- 108010049003 Fibrinogen Proteins 0.000 description 5
- 102000008946 Fibrinogen Human genes 0.000 description 5
- 206010061218 Inflammation Diseases 0.000 description 5
- 102000003815 Interleukin-11 Human genes 0.000 description 5
- 108090000177 Interleukin-11 Proteins 0.000 description 5
- 208000007452 Plasmacytoma Diseases 0.000 description 5
- 241000700159 Rattus Species 0.000 description 5
- 230000008901 benefit Effects 0.000 description 5
- 230000004071 biological effect Effects 0.000 description 5
- 230000002950 deficient Effects 0.000 description 5
- 230000001419 dependent effect Effects 0.000 description 5
- 229940012952 fibrinogen Drugs 0.000 description 5
- 230000004054 inflammatory process Effects 0.000 description 5
- 239000003112 inhibitor Substances 0.000 description 5
- 229940074383 interleukin-11 Drugs 0.000 description 5
- 230000008569 process Effects 0.000 description 5
- 230000004044 response Effects 0.000 description 5
- 230000001225 therapeutic effect Effects 0.000 description 5
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 4
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- 102000002274 Matrix Metalloproteinases Human genes 0.000 description 4
- 108010000684 Matrix Metalloproteinases Proteins 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 4
- 241000283973 Oryctolagus cuniculus Species 0.000 description 4
- 206010033647 Pancreatitis acute Diseases 0.000 description 4
- 201000003229 acute pancreatitis Diseases 0.000 description 4
- 238000013459 approach Methods 0.000 description 4
- 201000011510 cancer Diseases 0.000 description 4
- 230000010261 cell growth Effects 0.000 description 4
- 231100000433 cytotoxic Toxicity 0.000 description 4
- 230000001472 cytotoxic effect Effects 0.000 description 4
- 230000004069 differentiation Effects 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 230000002163 immunogen Effects 0.000 description 4
- 230000006698 induction Effects 0.000 description 4
- 208000015181 infectious disease Diseases 0.000 description 4
- 210000003734 kidney Anatomy 0.000 description 4
- 208000032839 leukemia Diseases 0.000 description 4
- 230000002503 metabolic effect Effects 0.000 description 4
- 201000006417 multiple sclerosis Diseases 0.000 description 4
- FEMOMIGRRWSMCU-UHFFFAOYSA-N ninhydrin Chemical compound C1=CC=C2C(=O)C(O)(O)C(=O)C2=C1 FEMOMIGRRWSMCU-UHFFFAOYSA-N 0.000 description 4
- 239000012071 phase Substances 0.000 description 4
- 125000006239 protecting group Chemical group 0.000 description 4
- 230000009885 systemic effect Effects 0.000 description 4
- 238000002054 transplantation Methods 0.000 description 4
- YDJXDYKQMRNUSA-UHFFFAOYSA-N tri(propan-2-yl)silane Chemical compound CC(C)[SiH](C(C)C)C(C)C YDJXDYKQMRNUSA-UHFFFAOYSA-N 0.000 description 4
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 3
- 230000003844 B-cell-activation Effects 0.000 description 3
- 206010025323 Lymphomas Diseases 0.000 description 3
- 206010040070 Septic Shock Diseases 0.000 description 3
- 206010042971 T-cell lymphoma Diseases 0.000 description 3
- 208000027585 T-cell non-Hodgkin lymphoma Diseases 0.000 description 3
- WBWWGRHZICKQGZ-UHFFFAOYSA-N Taurocholic acid Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(=O)NCCS(O)(=O)=O)C)C1(C)C(O)C2 WBWWGRHZICKQGZ-UHFFFAOYSA-N 0.000 description 3
- 230000002159 abnormal effect Effects 0.000 description 3
- 208000026935 allergic disease Diseases 0.000 description 3
- 150000001412 amines Chemical class 0.000 description 3
- 150000003862 amino acid derivatives Chemical class 0.000 description 3
- 230000002917 arthritic effect Effects 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 210000000988 bone and bone Anatomy 0.000 description 3
- 238000005251 capillar electrophoresis Methods 0.000 description 3
- 238000012512 characterization method Methods 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 238000003776 cleavage reaction Methods 0.000 description 3
- 230000000875 corresponding effect Effects 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- 206010012601 diabetes mellitus Diseases 0.000 description 3
- 238000010790 dilution Methods 0.000 description 3
- 239000012895 dilution Substances 0.000 description 3
- 238000002330 electrospray ionisation mass spectrometry Methods 0.000 description 3
- 229940011871 estrogen Drugs 0.000 description 3
- 239000000262 estrogen Substances 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 239000012634 fragment Substances 0.000 description 3
- 125000000524 functional group Chemical group 0.000 description 3
- 210000005260 human cell Anatomy 0.000 description 3
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- 230000003211 malignant effect Effects 0.000 description 3
- 239000011159 matrix material Substances 0.000 description 3
- 201000008265 mesangial proliferative glomerulonephritis Diseases 0.000 description 3
- 238000012544 monitoring process Methods 0.000 description 3
- 230000000144 pharmacologic effect Effects 0.000 description 3
- 230000007017 scission Effects 0.000 description 3
- 230000036303 septic shock Effects 0.000 description 3
- 230000019491 signal transduction Effects 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 208000011580 syndromic disease Diseases 0.000 description 3
- 230000000451 tissue damage Effects 0.000 description 3
- 231100000827 tissue damage Toxicity 0.000 description 3
- 230000014616 translation Effects 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- FUOOLUPWFVMBKG-UHFFFAOYSA-N 2-Aminoisobutyric acid Chemical compound CC(C)(N)C(O)=O FUOOLUPWFVMBKG-UHFFFAOYSA-N 0.000 description 2
- SNDPXSYFESPGGJ-UHFFFAOYSA-N 2-aminopentanoic acid Chemical compound CCCC(N)C(O)=O SNDPXSYFESPGGJ-UHFFFAOYSA-N 0.000 description 2
- YEDUAINPPJYDJZ-UHFFFAOYSA-N 2-hydroxybenzothiazole Chemical compound C1=CC=C2SC(O)=NC2=C1 YEDUAINPPJYDJZ-UHFFFAOYSA-N 0.000 description 2
- 102000013142 Amylases Human genes 0.000 description 2
- 108010065511 Amylases Proteins 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 208000035473 Communicable disease Diseases 0.000 description 2
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 2
- KRHYYFGTRYWZRS-UHFFFAOYSA-N Fluorane Chemical compound F KRHYYFGTRYWZRS-UHFFFAOYSA-N 0.000 description 2
- 208000032843 Hemorrhage Diseases 0.000 description 2
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 2
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 2
- 102000005741 Metalloproteases Human genes 0.000 description 2
- 108010006035 Metalloproteases Proteins 0.000 description 2
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 2
- 208000002774 Paraproteinemias Diseases 0.000 description 2
- 201000004681 Psoriasis Diseases 0.000 description 2
- 206010037660 Pyrexia Diseases 0.000 description 2
- 208000001647 Renal Insufficiency Diseases 0.000 description 2
- 208000006265 Renal cell carcinoma Diseases 0.000 description 2
- 210000001744 T-lymphocyte Anatomy 0.000 description 2
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 125000002947 alkylene group Chemical group 0.000 description 2
- 125000000539 amino acid group Chemical group 0.000 description 2
- 208000007502 anemia Diseases 0.000 description 2
- HOPRXXXSABQWAV-UHFFFAOYSA-N anhydrous collidine Natural products CC1=CC=NC(C)=C1C HOPRXXXSABQWAV-UHFFFAOYSA-N 0.000 description 2
- 230000003042 antagnostic effect Effects 0.000 description 2
- 229910052786 argon Inorganic materials 0.000 description 2
- 210000002469 basement membrane Anatomy 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- UTBIMNXEDGNJFE-UHFFFAOYSA-N collidine Natural products CC1=CC=C(C)C(C)=N1 UTBIMNXEDGNJFE-UHFFFAOYSA-N 0.000 description 2
- 239000012043 crude product Substances 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000007123 defense Effects 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 239000002158 endotoxin Substances 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 238000007429 general method Methods 0.000 description 2
- 239000003102 growth factor Substances 0.000 description 2
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 2
- 208000003669 immune deficiency disease Diseases 0.000 description 2
- 239000002596 immunotoxin Substances 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 238000005462 in vivo assay Methods 0.000 description 2
- 230000008595 infiltration Effects 0.000 description 2
- 238000001764 infiltration Methods 0.000 description 2
- 208000027866 inflammatory disease Diseases 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 230000002452 interceptive effect Effects 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 201000006370 kidney failure Diseases 0.000 description 2
- 238000011813 knockout mouse model Methods 0.000 description 2
- 210000001165 lymph node Anatomy 0.000 description 2
- 230000036210 malignancy Effects 0.000 description 2
- 238000004949 mass spectrometry Methods 0.000 description 2
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 210000002997 osteoclast Anatomy 0.000 description 2
- 210000000496 pancreas Anatomy 0.000 description 2
- 230000007170 pathology Effects 0.000 description 2
- 208000031223 plasma cell leukemia Diseases 0.000 description 2
- 230000036470 plasma concentration Effects 0.000 description 2
- 210000004180 plasmocyte Anatomy 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
- 238000000159 protein binding assay Methods 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- 238000012552 review Methods 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- GFYHSKONPJXCDE-UHFFFAOYSA-N sym-collidine Natural products CC1=CN=C(C)C(C)=C1 GFYHSKONPJXCDE-UHFFFAOYSA-N 0.000 description 2
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 2
- ADOHASQZJSJZBT-SANMLTNESA-N (2s)-2-(9h-fluoren-9-ylmethoxycarbonylamino)-3-[1-[(2-methylpropan-2-yl)oxycarbonyl]indol-3-yl]propanoic acid Chemical compound C12=CC=CC=C2N(C(=O)OC(C)(C)C)C=C1C[C@@H](C(O)=O)NC(=O)OCC1C2=CC=CC=C2C2=CC=CC=C21 ADOHASQZJSJZBT-SANMLTNESA-N 0.000 description 1
- SJVFAHZPLIXNDH-QFIPXVFZSA-N (2s)-2-(9h-fluoren-9-ylmethoxycarbonylamino)-3-phenylpropanoic acid Chemical compound C([C@@H](C(=O)O)NC(=O)OCC1C2=CC=CC=C2C2=CC=CC=C21)C1=CC=CC=C1 SJVFAHZPLIXNDH-QFIPXVFZSA-N 0.000 description 1
- CBPJQFCAFFNICX-IBGZPJMESA-N (2s)-2-(9h-fluoren-9-ylmethoxycarbonylamino)-4-methylpentanoic acid Chemical compound C1=CC=C2C(COC(=O)N[C@@H](CC(C)C)C(O)=O)C3=CC=CC=C3C2=C1 CBPJQFCAFFNICX-IBGZPJMESA-N 0.000 description 1
- UMRUUWFGLGNQLI-QFIPXVFZSA-N (2s)-2-(9h-fluoren-9-ylmethoxycarbonylamino)-6-[(2-methylpropan-2-yl)oxycarbonylamino]hexanoic acid Chemical compound C1=CC=C2C(COC(=O)N[C@@H](CCCCNC(=O)OC(C)(C)C)C(O)=O)C3=CC=CC=C3C2=C1 UMRUUWFGLGNQLI-QFIPXVFZSA-N 0.000 description 1
- VYRYMCNWIVZAGH-QMMMGPOBSA-N (2s)-2-(fluoroamino)-3-phenylpropanoic acid Chemical compound OC(=O)[C@@H](NF)CC1=CC=CC=C1 VYRYMCNWIVZAGH-QMMMGPOBSA-N 0.000 description 1
- RWLSBXBFZHDHHX-VIFPVBQESA-N (2s)-2-(naphthalen-2-ylamino)propanoic acid Chemical compound C1=CC=CC2=CC(N[C@@H](C)C(O)=O)=CC=C21 RWLSBXBFZHDHHX-VIFPVBQESA-N 0.000 description 1
- SAAQPSNNIOGFSQ-LURJTMIESA-N (2s)-2-(pyridin-4-ylamino)propanoic acid Chemical compound OC(=O)[C@H](C)NC1=CC=NC=C1 SAAQPSNNIOGFSQ-LURJTMIESA-N 0.000 description 1
- DVBUCBXGDWWXNY-SFHVURJKSA-N (2s)-5-(diaminomethylideneamino)-2-(9h-fluoren-9-ylmethoxycarbonylamino)pentanoic acid Chemical compound C1=CC=C2C(COC(=O)N[C@@H](CCCN=C(N)N)C(O)=O)C3=CC=CC=C3C2=C1 DVBUCBXGDWWXNY-SFHVURJKSA-N 0.000 description 1
- QTWZCODKTSUZJN-LJAQVGFWSA-N (2s)-5-[[amino-[(2,2,5,7,8-pentamethyl-3,4-dihydrochromen-6-yl)sulfonylamino]methylidene]amino]-2-(9h-fluoren-9-ylmethoxycarbonylamino)pentanoic acid Chemical compound C12=CC=CC=C2C2=CC=CC=C2C1COC(=O)N[C@H](C(O)=O)CCCN=C(N)NS(=O)(=O)C(C(C)=C1C)=C(C)C2=C1OC(C)(C)CC2 QTWZCODKTSUZJN-LJAQVGFWSA-N 0.000 description 1
- DHBXNPKRAUYBTH-UHFFFAOYSA-N 1,1-ethanedithiol Chemical compound CC(S)S DHBXNPKRAUYBTH-UHFFFAOYSA-N 0.000 description 1
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
- ASOKPJOREAFHNY-UHFFFAOYSA-N 1-Hydroxybenzotriazole Chemical compound C1=CC=C2N(O)N=NC2=C1 ASOKPJOREAFHNY-UHFFFAOYSA-N 0.000 description 1
- WPWHSFAFEBZWBB-UHFFFAOYSA-N 1-butyl radical Chemical group [CH2]CCC WPWHSFAFEBZWBB-UHFFFAOYSA-N 0.000 description 1
- BLCJBICVQSYOIF-UHFFFAOYSA-N 2,2-diaminobutanoic acid Chemical compound CCC(N)(N)C(O)=O BLCJBICVQSYOIF-UHFFFAOYSA-N 0.000 description 1
- WTOFYLAWDLQMBZ-UHFFFAOYSA-N 2-azaniumyl-3-thiophen-2-ylpropanoate Chemical compound OC(=O)C(N)CC1=CC=CS1 WTOFYLAWDLQMBZ-UHFFFAOYSA-N 0.000 description 1
- PECYZEOJVXMISF-REOHCLBHSA-N 3-amino-L-alanine Chemical compound [NH3+]C[C@H](N)C([O-])=O PECYZEOJVXMISF-REOHCLBHSA-N 0.000 description 1
- PECYZEOJVXMISF-UHFFFAOYSA-N 3-aminoalanine Chemical compound [NH3+]CC(N)C([O-])=O PECYZEOJVXMISF-UHFFFAOYSA-N 0.000 description 1
- CMUHFUGDYMFHEI-QMMMGPOBSA-N 4-amino-L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(N)C=C1 CMUHFUGDYMFHEI-QMMMGPOBSA-N 0.000 description 1
- PMQQFSDIECYOQV-UHFFFAOYSA-N 5,5-dimethyl-1,3-thiazolidin-3-ium-4-carboxylate Chemical compound CC1(C)SCNC1C(O)=O PMQQFSDIECYOQV-UHFFFAOYSA-N 0.000 description 1
- 208000010444 Acidosis Diseases 0.000 description 1
- 208000009663 Acute Necrotizing Pancreatitis Diseases 0.000 description 1
- 239000004382 Amylase Substances 0.000 description 1
- 206010003445 Ascites Diseases 0.000 description 1
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 description 1
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- 208000010392 Bone Fractures Diseases 0.000 description 1
- 208000006386 Bone Resorption Diseases 0.000 description 1
- 206010006002 Bone pain Diseases 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 108010074051 C-Reactive Protein Proteins 0.000 description 1
- 102100032752 C-reactive protein Human genes 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 206010009192 Circulatory collapse Diseases 0.000 description 1
- CHBRHODLKOZEPZ-UHFFFAOYSA-N Clotiazepam Chemical compound S1C(CC)=CC2=C1N(C)C(=O)CN=C2C1=CC=CC=C1Cl CHBRHODLKOZEPZ-UHFFFAOYSA-N 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N Cysteine Chemical compound SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- OUYCCCASQSFEME-MRVPVSSYSA-N D-tyrosine Chemical compound OC(=O)[C@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-MRVPVSSYSA-N 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 208000017701 Endocrine disease Diseases 0.000 description 1
- 101710121417 Envelope glycoprotein Proteins 0.000 description 1
- 208000031637 Erythroblastic Acute Leukemia Diseases 0.000 description 1
- 208000036566 Erythroleukaemia Diseases 0.000 description 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
- 206010061857 Fat necrosis Diseases 0.000 description 1
- NIGWMJHCCYYCSF-UHFFFAOYSA-N Fenclonine Chemical compound OC(=O)C(N)CC1=CC=C(Cl)C=C1 NIGWMJHCCYYCSF-UHFFFAOYSA-N 0.000 description 1
- 230000005526 G1 to G0 transition Effects 0.000 description 1
- 208000018522 Gastrointestinal disease Diseases 0.000 description 1
- 206010060891 General symptom Diseases 0.000 description 1
- ARPVSMCNIDAQBO-YUMQZZPRSA-N Gln-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@@H](N)CCC(N)=O ARPVSMCNIDAQBO-YUMQZZPRSA-N 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 208000031886 HIV Infections Diseases 0.000 description 1
- 208000037357 HIV infectious disease Diseases 0.000 description 1
- 208000017604 Hodgkin disease Diseases 0.000 description 1
- 208000021519 Hodgkin lymphoma Diseases 0.000 description 1
- 208000010747 Hodgkins lymphoma Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101001076408 Homo sapiens Interleukin-6 Proteins 0.000 description 1
- 101000611183 Homo sapiens Tumor necrosis factor Proteins 0.000 description 1
- 208000037147 Hypercalcaemia Diseases 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- 208000013016 Hypoglycemia Diseases 0.000 description 1
- 206010061598 Immunodeficiency Diseases 0.000 description 1
- 102100034349 Integrase Human genes 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 108010002350 Interleukin-2 Proteins 0.000 description 1
- 102100037792 Interleukin-6 receptor subunit alpha Human genes 0.000 description 1
- 108090001007 Interleukin-8 Proteins 0.000 description 1
- 102000004890 Interleukin-8 Human genes 0.000 description 1
- SNDPXSYFESPGGJ-BYPYZUCNSA-N L-2-aminopentanoic acid Chemical compound CCC[C@H](N)C(O)=O SNDPXSYFESPGGJ-BYPYZUCNSA-N 0.000 description 1
- QUOGESRFPZDMMT-UHFFFAOYSA-N L-Homoarginine Natural products OC(=O)C(N)CCCCNC(N)=N QUOGESRFPZDMMT-UHFFFAOYSA-N 0.000 description 1
- QUOGESRFPZDMMT-YFKPBYRVSA-N L-homoarginine Chemical compound OC(=O)[C@@H](N)CCCCNC(N)=N QUOGESRFPZDMMT-YFKPBYRVSA-N 0.000 description 1
- FFFHZYDWPBMWHY-VKHMYHEASA-N L-homocysteine Chemical compound OC(=O)[C@@H](N)CCS FFFHZYDWPBMWHY-VKHMYHEASA-N 0.000 description 1
- 102000004058 Leukemia inhibitory factor Human genes 0.000 description 1
- 108090000581 Leukemia inhibitory factor Proteins 0.000 description 1
- 102000004882 Lipase Human genes 0.000 description 1
- 108090001060 Lipase Proteins 0.000 description 1
- 239000004367 Lipase Substances 0.000 description 1
- 102000005482 Lipopolysaccharide Receptors Human genes 0.000 description 1
- 108010031801 Lipopolysaccharide Receptors Proteins 0.000 description 1
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 description 1
- NPBGTPKLVJEOBE-IUCAKERBSA-N Lys-Arg Chemical compound NCCCC[C@H](N)C(=O)N[C@H](C(O)=O)CCCNC(N)=N NPBGTPKLVJEOBE-IUCAKERBSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 206010027417 Metabolic acidosis Diseases 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 241000699660 Mus musculus Species 0.000 description 1
- 241000187479 Mycobacterium tuberculosis Species 0.000 description 1
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 description 1
- 125000000729 N-terminal amino-acid group Chemical group 0.000 description 1
- 206010028851 Necrosis Diseases 0.000 description 1
- 101100030361 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) pph-3 gene Proteins 0.000 description 1
- 206010053159 Organ failure Diseases 0.000 description 1
- 206010058096 Pancreatic necrosis Diseases 0.000 description 1
- 241001111421 Pannus Species 0.000 description 1
- 241000700157 Rattus norvegicus Species 0.000 description 1
- 102000005157 Somatostatin Human genes 0.000 description 1
- 108010056088 Somatostatin Proteins 0.000 description 1
- 230000024932 T cell mediated immunity Effects 0.000 description 1
- 239000012317 TBTU Substances 0.000 description 1
- 102100040247 Tumor necrosis factor Human genes 0.000 description 1
- 206010064390 Tumour invasion Diseases 0.000 description 1
- STTYIMSDIYISRG-UHFFFAOYSA-N Valyl-Serine Chemical compound CC(C)C(N)C(=O)NC(CO)C(O)=O STTYIMSDIYISRG-UHFFFAOYSA-N 0.000 description 1
- SORGEQQSQGNZFI-UHFFFAOYSA-N [azido(phenoxy)phosphoryl]oxybenzene Chemical compound C=1C=CC=CC=1OP(=O)(N=[N+]=[N-])OC1=CC=CC=C1 SORGEQQSQGNZFI-UHFFFAOYSA-N 0.000 description 1
- CLZISMQKJZCZDN-UHFFFAOYSA-N [benzotriazol-1-yloxy(dimethylamino)methylidene]-dimethylazanium Chemical compound C1=CC=C2N(OC(N(C)C)=[N+](C)C)N=NC2=C1 CLZISMQKJZCZDN-UHFFFAOYSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 208000021841 acute erythroid leukemia Diseases 0.000 description 1
- 208000038016 acute inflammation Diseases 0.000 description 1
- 230000006022 acute inflammation Effects 0.000 description 1
- 230000001270 agonistic effect Effects 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 150000001350 alkyl halides Chemical class 0.000 description 1
- 150000001371 alpha-amino acids Chemical class 0.000 description 1
- 235000008206 alpha-amino acids Nutrition 0.000 description 1
- 229940124277 aminobutyric acid Drugs 0.000 description 1
- 235000019418 amylase Nutrition 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000003466 anti-cipated effect Effects 0.000 description 1
- 230000003460 anti-nuclear Effects 0.000 description 1
- 230000000692 anti-sense effect Effects 0.000 description 1
- 125000000732 arylene group Chemical group 0.000 description 1
- 125000004429 atom Chemical group 0.000 description 1
- 230000003416 augmentation Effects 0.000 description 1
- 230000003305 autocrine Effects 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- 230000005784 autoimmunity Effects 0.000 description 1
- KCXMKQUNVWSEMD-UHFFFAOYSA-N benzyl chloride Chemical compound ClCC1=CC=CC=C1 KCXMKQUNVWSEMD-UHFFFAOYSA-N 0.000 description 1
- 229940073608 benzyl chloride Drugs 0.000 description 1
- 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 description 1
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 229920001222 biopolymer Polymers 0.000 description 1
- 208000034158 bleeding Diseases 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 210000002449 bone cell Anatomy 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 210000002798 bone marrow cell Anatomy 0.000 description 1
- 230000024279 bone resorption Effects 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 125000001246 bromo group Chemical group Br* 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 230000009400 cancer invasion Effects 0.000 description 1
- 150000001735 carboxylic acids Chemical class 0.000 description 1
- 210000000845 cartilage Anatomy 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 208000019065 cervical carcinoma Diseases 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 description 1
- 230000009918 complex formation Effects 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 125000002993 cycloalkylene group Chemical group 0.000 description 1
- 102000003675 cytokine receptors Human genes 0.000 description 1
- 108010057085 cytokine receptors Proteins 0.000 description 1
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000000593 degrading effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 230000001236 detergent effect Effects 0.000 description 1
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 1
- 229960003957 dexamethasone Drugs 0.000 description 1
- 230000010339 dilation Effects 0.000 description 1
- 238000006471 dimerization reaction Methods 0.000 description 1
- MKRTXPORKIRPDG-UHFFFAOYSA-N diphenylphosphoryl azide Chemical compound C=1C=CC=CC=1P(=O)(N=[N+]=[N-])C1=CC=CC=C1 MKRTXPORKIRPDG-UHFFFAOYSA-N 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 238000009510 drug design Methods 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 230000008482 dysregulation Effects 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 230000003628 erosive effect Effects 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 210000002744 extracellular matrix Anatomy 0.000 description 1
- 210000003414 extremity Anatomy 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 230000014509 gene expression Effects 0.000 description 1
- 238000010363 gene targeting Methods 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 208000014951 hematologic disease Diseases 0.000 description 1
- 230000002489 hematologic effect Effects 0.000 description 1
- 230000011132 hemopoiesis Effects 0.000 description 1
- 239000000833 heterodimer Substances 0.000 description 1
- 230000013632 homeostatic process Effects 0.000 description 1
- 102000052611 human IL6 Human genes 0.000 description 1
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 description 1
- 230000028996 humoral immune response Effects 0.000 description 1
- 210000004408 hybridoma Anatomy 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
- 230000000148 hypercalcaemia Effects 0.000 description 1
- 208000030915 hypercalcemia disease Diseases 0.000 description 1
- 201000001421 hyperglycemia Diseases 0.000 description 1
- 230000002218 hypoglycaemic effect Effects 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 208000026278 immune system disease Diseases 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 239000002955 immunomodulating agent Substances 0.000 description 1
- 229940121354 immunomodulator Drugs 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000004968 inflammatory condition Effects 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- 230000017306 interleukin-6 production Effects 0.000 description 1
- 108040006858 interleukin-6 receptor activity proteins Proteins 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 150000002611 lead compounds Chemical class 0.000 description 1
- 231100000225 lethality Toxicity 0.000 description 1
- 238000011694 lewis rat Methods 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 235000019421 lipase Nutrition 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 210000003141 lower extremity Anatomy 0.000 description 1
- 206010025135 lupus erythematosus Diseases 0.000 description 1
- MVCNPXUMKZNDRO-OAHLLOKOSA-N lysergene Chemical compound C1=CC(C2=CC(=C)CN([C@@H]2C2)C)=C3C2=CNC3=C1 MVCNPXUMKZNDRO-OAHLLOKOSA-N 0.000 description 1
- 238000013507 mapping Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 230000004660 morphological change Effects 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 230000002956 necrotizing effect Effects 0.000 description 1
- 201000008383 nephritis Diseases 0.000 description 1
- 231100000065 noncytotoxic Toxicity 0.000 description 1
- 230000002020 noncytotoxic effect Effects 0.000 description 1
- 238000011580 nude mouse model Methods 0.000 description 1
- 238000009806 oophorectomy Methods 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 230000004768 organ dysfunction Effects 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 230000001599 osteoclastic effect Effects 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 238000012335 pathological evaluation Methods 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 210000003200 peritoneal cavity Anatomy 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 238000002823 phage display Methods 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 230000004983 pleiotropic effect Effects 0.000 description 1
- 208000001685 postmenopausal osteoporosis Diseases 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000002250 progressing effect Effects 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 230000035484 reaction time Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000007634 remodeling Methods 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000000452 restraining effect Effects 0.000 description 1
- 238000007423 screening assay Methods 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000003375 selectivity assay Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 206010040560 shock Diseases 0.000 description 1
- 230000008054 signal transmission Effects 0.000 description 1
- 239000002356 single layer Substances 0.000 description 1
- JAJWGJBVLPIOOH-IZYKLYLVSA-M sodium taurocholate Chemical compound [Na+].C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCCS([O-])(=O)=O)C)[C@@]2(C)[C@@H](O)C1 JAJWGJBVLPIOOH-IZYKLYLVSA-M 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- NHXLMOGPVYXJNR-ATOGVRKGSA-N somatostatin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N1)[C@@H](C)O)NC(=O)CNC(=O)[C@H](C)N)C(O)=O)=O)[C@H](O)C)C1=CC=CC=C1 NHXLMOGPVYXJNR-ATOGVRKGSA-N 0.000 description 1
- 229960000553 somatostatin Drugs 0.000 description 1
- 125000006850 spacer group Chemical group 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 125000005717 substituted cycloalkylene group Chemical group 0.000 description 1
- 230000003319 supportive effect Effects 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 210000001179 synovial fluid Anatomy 0.000 description 1
- 210000001258 synovial membrane Anatomy 0.000 description 1
- 210000005222 synovial tissue Anatomy 0.000 description 1
- 201000004595 synovitis Diseases 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 238000011521 systemic chemotherapy Methods 0.000 description 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 150000003573 thiols Chemical class 0.000 description 1
- 229940104230 thymidine Drugs 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 230000007888 toxin activity Effects 0.000 description 1
- 108700012359 toxins Proteins 0.000 description 1
- 230000000472 traumatic effect Effects 0.000 description 1
- ZGYICYBLPGRURT-UHFFFAOYSA-N tri(propan-2-yl)silicon Chemical compound CC(C)[Si](C(C)C)C(C)C ZGYICYBLPGRURT-UHFFFAOYSA-N 0.000 description 1
- UCPYLLCMEDAXFR-UHFFFAOYSA-N triphosgene Chemical compound ClC(Cl)(Cl)OC(=O)OC(Cl)(Cl)Cl UCPYLLCMEDAXFR-UHFFFAOYSA-N 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/5412—IL-6
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
- C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Description
((
N
CONFORMATIONALLY CONSTRAINED RBRACKBONE
CYCLIZED INTERLEUKIN-6 ANTAGONISTS
The present invention relates to conformationally constrained backbone-cyclized IL-6 antagonists, and to pharmaceutical compositions containing same.
Interleukin-6 (IL-6) is a member of the helical cytokine family. IL-6 is produced by almost all cell types in response to a variety of different stimuli including bacterial (LPS) and viral infections, cancer, and other cytokines (e.g. IL-1). IL-6 is a pleiotropic factor, it participates in numerous processes and is thus associated with numerous disorders (for a review see Hirano T., Intern. Rev. Immunol. 16:249, 1998).
Bioactivity of IL-6 requires interaction of the cytokine, IL-6, its receptor (IL-6R) and a transmembrane signal transducer known as glycoprotein 130 (gpl130), and formation of a hexameric complex containing two units of each protein. The outcome of the complex formation is dimerization of gpl30, which by itself is sufficient for obtaining IL-6 like bioactivity (Fourcin, et al., J. Biol. Chem. 271: 11756, 1996.). Several other cytokines also use gpl30 for signal transduction. These include: interleukin-11 (IL-11), ciliary neurotrophic factor (CNTF), leukocyte inhibitory factor (LIF), oncostatin M (OSM).
IL-6 and host defense
IL-6 levels increases early during bacterial and viral infections. IL-6 induces production of acute phase proteins which are thought to participate in the defense of the host organism against tissue damage and infection. The acute phase response is considered to be the systemic inflammatory reaction to infection and injury.
IL-6 also amplifies the immune system through its multiple growth and differentiation activities such as induction of BR cell differentiaticn, replication of bone marrow progenitor cells, and augmentation of T lymphocytes, including enhancement of cytotoxic T lymphocytes.
IL-6 in homeostasis, injury and transplantation:
IL-6 levels are increased during stress. IL-6 in rabbits is directly responsible for elevation of body temperature. High
IL-6 levels in burn patients correlates with mortality.
Elevated IL-6 levels are associated with traumatic events and allograft rejection.
IL-6 in Osteoporosis:
Estrogen plays an important role in maintaining bone mass. A massive loss of bone mass is reported in women at there postmenopausal stage. Increased bone resorption and increased osteoclast activity in postmenopausal osteoporosis have been linked with IL-6. The production of IL-6 is elevated in bone marrow cells at this stage correlating the fact that estrogen down regulates IL-6 gene expression. Estrogen loss induced by ovariectomy in mice enhances osteoclast development and this change can be prevented by antibodies to IL-6. Several experiments including an IL-6 knockout mice model, treatment with anti IL-6 antibodies or with IL-6 antisense demonstrate that elevated levels of IL-6 plays a critical role in the formation of osteoclastic cells. As such, dysregulation of IL-6 activity in bone cells leads to the development of pathological disease.
IL-6 in immune disorders
Elevated levels of IL-6 in cardiac myxoma and cervical carcinoma are associated with autoimmunity indications such as: production of anti-nuclear factor, rheumatoid factors, elevated immune complexes, arthritis and nephritis.
Castelman's disease patients suffer form fever, anemia, hyper-y-globulinemia, and an increase in acute phase proteins.
The lymph nodes constitutively produce large amounts of IL-6, and surgical removal of the involved lymph nodes is followed by decrease in serum IL-6 levels and a dramatic clinical improvement. It has been demonstrated that systemic manifestation of Castelman's disease could be alleviated by treatment with anti-IL-6 antibody.
Local and general symptoms of rheumatoid arthritis, such as plasma cell infiltration into synovial tissues, autcantibody production, and polyclonal hyper-vy-globulinemia can be exr_=airsd kr inmcressed IL-2 produztisn IZssrTsZ Zo oErTmoTLal tissue. RT L=53%T twWC mMBCIlsTCIE which =e s=lsTE=ITEZ LT Se patients, P3EZ and IL-1, are xnown To imZuce simthesis co IT-0.
Higher than normal levels oZ IL-€ haves been detected in sera cf patients with active SLE. Increased plasma levels of IL-6 were observed in psoriasis patients.
AIDS:
High levels of IL-6 are associated with HIV infection. The HIV envelope glycoproteins gpl20 and gpl60 induce IL-6 production from CD4+ T cells. Is has been demonstrated that IL-6 is a growtn factor of the AIDS associated Kaposi's sarcoma (Murakamin-Mori, et al. Int. Immunol. £8: 595, 198€). The soluble form of the IL-6 receptor {sIL-6Ra) is a potent growth factor for AIDS-associated Kaposi's sarcoma (KS) cells. The soluble form of gpl30 is antagonistic for sIL-6Ra-induced
AIDS-KS cell growth. Furthermore, high IL-6 levels are associated with weight loss in AIDS.
Proliferative diseases and malignancies
An autocrine role for IL-6 has been reported in several types of cancer, among which are renal cell carcinoma, Hodgkin and non-Hodgkin's lymphoma, chronic lymphocytic leukemia, and acute myeloid leukemias. Plasmacytoma and myeloma cells require IL-6 for growth. Treatment of primary plasma cell leukemia with anti-IL-6 antibodies improves the patient's clinical status throughout the treatment. Also, IL-6 deficient mice are completely resistant to plasmacytoma induction.
Multiple myeloma is a malignant proliferation of plasma cells derived from a single clone. It is manifested in a number of organ dysfunctions and symptoms of bone pain or fractures, hypercalcemia, renal failure, susceptibility to infection, anemia and bleeding. The disease typically follows a chronic course for 2 to 5 years before progressing into an acute terminal phase.
The different therapeutic strategies for inhibition of multiple myeloma have been recently reviewed (Ogata A., Leuk. Res. 20 : 303, 1996). The vast majority of multiple myeloma patients require systemic chemotherapy to control the malignancy, and symptomatic supportive care to minimize the morbidity. The outcome of patients with multiple myeloma is still unsatisfactory, with median survival times of 2 to 3 years.
Clearly, there is a need for an agent that cannot only improve the chances of remission, but also increase the duration of response and enhance survival. : Recently, injection of an anti-IL-6 antibody was tested in young population and resulted in a complete blocking of myeloma cell proliferation and inhibition of the serum IL-6 bioactivity. However, the administration of a single anti-IL-6 mAb appeared to be insufficient (Klein, et al., Blood 85: 863, 1999).
IL-6 has also a regulatory role in activation of Matrix
Metalloproteinases (MMPs). MMPs are enzymes that are capable degrading the basement membrane components. As such MMPs are refereed as key enzymes in Extra Cellular Matrix remodeling, tumor invasion and metastasis.
Inhibitors of IL-6 activity
It is generally accepted that IL-6 inhibitors have clinical value. As indicated above there are a number of clinical situations where IL-6 inhibitors could be of therapeutic use.
Most of the attempts to produced inhibitors to IL-6 reported in the literature in the past, used proteins. In general, proteins are not very suitable as drugs, due to their immunogenic potential, high cost, and the necessity for parenteral administration. The various attempts to use proteins to inhibit
IL-6 are described below.
Monoclonal antibodies and antibody fragments:
The most common approach is to use monoclonal antibodies (mAbs). Several murine mAbs capable of inhibiting the bioactivity of IL-6 have been described.
The drawbacks in the use of antibodies against IL-6 are that “he mA Trzps the I1-% In =n Immune Complex IT Tne CSirsulzToicon
May eT al., _-. Immuncl. IED, 222%, 12092), thereby InorszsEing its half-life 200-fcld (Lu et al., BlocZ 8g, Z12Z,2:z:=Z,. Ths immune complexes are thus serve as long term, slow release deposits of IL-6. The presence of high levels of circulating immune complexes could result in their precipitation in the basal lamina in the kidneys or in the joints, which could lead to kidney failure or arthritis.
Attempts to block IL-6 with monoclonal antibodies have been reported for the following diseases: AIDS associated syndromes and lymphoma (Emilie, et al., 3lcod 84: 2472, 1994;,
Castelman's disease, rheumatoid arthritis (Wijdenes et al., J.
Interferon Res. 14: 297, 1994, Yoshizaki et al. Springer Semin.
Immunopathol., 20:247, 1998), multiple myeloma, plasma cell leukemia (Klein et al., Blood 78: 1198, 1991), and endotoxin toxicity. Partial response were observe in most instances, but the problems associated with the use of monoclonal antibodies for inhibition of IL-6 have so far prevented their routine clinical application.
Some of problems associated with the clinical use of monoclonal antibodies are a result of the large size of the antibody molecule. Minibodies which utilize the hypervariable loop structure of antibodies, capable of inhibiting IL-6 bioactivity were recently reported (Martin et al., The EMBO J. 13, 5303, 1994). Binding of IL-6 to a minibody molecule should create a complex that is small enough to be secreted from the kidney, thereby decreasing the risk of creating slow release IL-6 deposits. Minibody-IL-6 complexes may not be recognized as immune complexes, thereby decreasing the chances for kidneys and arthritic problems. The minibodies could still be immunogenic and it is unlikely that they will be orally available. So far, minibodies with sufficiently high affinity for IL-6 have not been obtained.
Mutated proteins:
Several IL-6 mutants were selected for desired activity using phage display systems. Super active mutants were reported (Toniatti, et al., The EMBO J. 15: 2726, 1996) as well as mutants which retain the capacity for binding of the IL-6R but lose the ability for interaction with the gpl30 and thus could serve as functional antagonists of IL-6 bioactivity (Savino et al., The EMBO J. 13,5863, 1994; Sporeno, et al., Blood 87: : 4510, 1996). The danger in clinical use of such mutants is the formation of antibodies that would recognize both the mutated : 20 and the native molecules. Such antibodies could block the bicactivity of IL-6 long after the treatment is terminated thereby exposing the patients to danger associated with lack of
IL-6.
US Patent No. 5,470,952 disclose CTNF and IL-6 antagonists which are heterodimer proteins comprising a soluble g specificity determining cytokine receptor component and the extracellular domain of a B receptor component. Specifically, the inventors claim an IL-6 antagonist, capable of binding IL-6 to form a nonfunctional complex, comprising: soluble IL-6Rg and the extracellular domain of gpl30.
Cytokine-toxin conjugates:
Several applications of IL-6 inhibitors entail the elimination of IL-6 dependent tumors, such as multiple myeloma. This goal can be achieved by the use of IL-6-toxin conjugate (Jean and
Murphy, Prot. Eng. 4, 989, 1991). Malignant cells that have receptor for IL-6 would bind the toxin via the IL-6 portion of the conjugate and would be eliminated by toxin activity.
Toxicity to all non-malignant cells that also express the IL-6 receptor is a dangerous possibility. Since IL-6 is required for development of normal humoral and cellular immune response, it is possible to speculate that treated patients would immunocompromised.
Peptide antagonists of IL-6
Grubs zm Cochran Identified z regulstors Zomslzn ZI ths 11-2 r2zszzTcr (J. Bizl. Chem. zfs: ZIT:I, 1zz4 0 Toe Ts=zizn os Zoo the extramemtrzanal domain of fhe I1-£€2 andi 1% 1s ZnToliTes oo the regulation of IL-6 signal transmission. A synthetic peptide, corresponding to residues 249-264 of the IL-6R inhibits IL-6-dependent cell mitogenesis and IL-6-stimulated acute phase response without affecting ligand binding.
In a search for possible lead compounds, epitope mapping of the human IL-6R was carried out (Halimi et al., Eur. Cytokin, Netw. 6:135, 1995) with mAbs to IL-6R which inhibit the biological activity of IL-6 (Novick, et al., Hybridoma 10, 137, 1891). The 10 mer linear peptides that were recognized by two of the antibodies are from the same region identified by Grube and
Cochran (ibid). The peptides identified by these two groups are indicated in the frame of the IL-6R sequence in figure 1 (*
Grube and Cochran, ** Halimi et al.).
International PCT application WO 97/13781 discloses these synthetic peptides and analogs derived from the IL-6 that inhibit IL-6 activity. The peptides claimed are characterized also by being a linear epitope recognized by one or more Mabs specific to IL-6R. Peptides 1122 and 1123 (Halimi et al. ibid), were synthesized and found to inhibit IL-6 biocactivity in vitro with an IDso of about 100 pM.
International PCT application WO 95/13086 and US patent 5,420,109, discloses peptides which are cytokine restraining agents having the general formula: X1-X2-His-DPhe-Arg-DTrp-X3.
These peptides are non-specific agents which modulate the activity of various cytokines (TNF, IL-1, IL-6 and IL-8) simultaneously, and therefore are not specific IL-6 inhibitors.
International PCT application WO 97/48728, discloses synthetic peptides which derived from IL-6 and from IL-6 receptor (either the IL-6R or gpl30), and have IL-6 antagonistic or agonistic activity. The peptides interact with the receptor site of IL-6 or with IL-6Rs present at target cells or when combined, interact with both sites (IL-6 and IL-6R).
US Patent No. 5,210,075 discloses IL-6 antagonist peptides of varying length, which are modeled after a portion of the sequence of IL-6 itself (p51-70 Hirano et al. Nature 324:73, 1986), or which are modeled after four different portions of the sequence of the IL-6 receptor molecule.
None of these disclose conformationally constrained IL-6 peptide antagonists which are cyclized as described in the present invention.
Peptide mimetic and backbone cyclized peptide analog antagonists of IL-6
It is most beneficial to produce conformationally constrained peptide analogs overcoming the drawbacks of the native peptide molecules (low metabolic stability, poor oral bio-availability, rapid liver and kidney excretion, and lack of selectivity), thereby providing improved therapeutic properties.
A novel conceptual approach to the conformational constraint of peptides was introduced by Gilon, et al., (Biopolymers 31:745, 1991), who proposed backbone to backbone cyclization of peptides. The theoretical advantages of this strategy include the ability to effect cyclization via the carbons or nitrogens of the peptide backbone without interfering with side chains that may be crucial for interaction with the specific receptor of a given peptide.
Further disclosure by Gilon and coworkers (WO 95/33765) provided methods for producing building units required in the synthesis of backbone cyclized peptide analogs. Recently, The successful use of these methods to produce backbone cyclized peptide analogs having somatostatin activity was also disclosed (WO 88/04583 and WO 99/65508). Libraries of backbone cyclized analicgs including IL-6 analcgs are disclosed in international’ application WO 87/09344. In <hat disclosure, a selsctizn method termed “YCyclcscan”, fz=zsf con confcrmaticnally coostrs=icec tazkbone cyclic peptide libraries that allows rapiz Zetscticn of active analogs derived from a given sequence is described.
Nowhere in the background art, are backbone cyclized peptide analogs shown to possess IL-6 inhibitory activity.
It is an object of the present invention to provide novel peptide analogs, which are characterized in that they incorporate building units with bridging groups attached to the alpha nitrogens of alpha amino acids, having IL-6 inhibitory activity. Specifically, these compounds are backbone cyclized
IL-6 antagonists comprising a peptide sequence of five to twenty amino acids that incorporates at least one building unit, said building unit containing one nitrogen atom of the peptide backbone connected to a bridging group comprising an amide, thioether, thioester or disulfide, wherein the at least one building unit is connected via said bridging group to form a cyclic structure with a moiety selected from the group consisting of a second building unit, the side chain of an amino acid residue of the sequence or the N-terminal amino acid residue. Preferably, the peptide sequence incorporates six to twelve amino acids, having IL-6 inhibitory activity.
Ce]
Bioactivity of IL-6 requires each of the molecules in the tripartite complex, i.e. IL-6, IL-6R and gpl30 signal transducer, to interact with the two other partners. The objectives of the present invention will be achieved by peptides that inhibit any one of interactions in the complex as follows: a) Peptides derived from IL-6 that interfere with IL-6-IL-6R interaction or with IL-6/gpl30 interaction. b) Peptides derived from IL-6R that interfere with IL-6-IL-6R interaction or with IL-6R/gpl30 interaction. c) Peptides derived from gpl30 that interfere with IL-6/gpl30 or with IL-6R/gpl30 interactions.
According to one aspect of the present invention, the segment of the IL-6R spanning residues 247-271 is currently a most preferred embodiment for development of conformationally constrained backbone cyclized peptide analogs to be used as an inhibitor of IL-6 activity. ’ 20 From the screening of backbone cyclized peptide analogs, preferred peptide analogs were unexpectedly found to have significantly enhanced inhibitory activity in comparison to the linear epitope. Some of these backbone cyclized peptide analogs mimic the IL-6R inhibitory domain of residues 249-258, others mimic the region in IL-6 which binds its receptor. But unlike the previously described peptides derived from these domains, these novel backbone cyclized peptide analogs possess unique features which make them more suitable for use in pharmaceutical compositions for treatment of pathological conditions associated with elevated levels of IL-6.
According to the present invention it is now disclosed that more preferred backbone cyclized analogs are decapeptide and nonapeptide antagonists of IL-6 with improved activity and metabolic stability. Additional more preferred analogs may advantageously include at least one D-isomer of amino acids in their sequence.
Preferably, the backbone cyclized analogs of the present invention are derived from, or mimic the sequence of the IL-6R molecule, preferzbly related to residues 247-271 of the IL-6R amino acids sequence. Additional preferred analogs are derived from the sequence of the IL-6 molecule.
A preferred embodiment of the present invention has the following formula:
HE A
.5 Formula No. 2 wherein m and n are 1 to 5;
X designates a terminal carboxy acid, amide or alcohol group;
R?® is Trp, (L) or (D)Lys, (L) or (D) Tyr or (D)Phe;
R*C is Arg;
R**! is (L) or (D)Leu or Lys;
R**? is (L) or (D)Arg;
R** is (D)- or (L)- Phe;
R*** is Ala;
R®*® is (D)- or (L)- Leu or is Lys;
R?>® is absent or is (L) or (D) Arg:
R**’ is (L) or (D) Tyr;
R**® is Ala; and
Y® is amide, thioether, thioester or disulfide.
A more preferred embodiment of the present invention has the following formula:
A
~ (CHz) n=¥*~ (CHz) p 40 Formula No. 2 wherein m and n are 1 to 5;
X designates a terminal carboxy acid, amide or alcohol group;
R%Y? is Trp, (D)Lys or (D)Phe;
R*° is Arg;
R*?! is Lys or (D)Leu;
R*? is (D)YArg:;
R**® is (D)- or (L)- Phe;
R*** is Ala;
R**® is (D)- or (L)- Leu;
R**® is absent or is Arg;
R?7 is (D) Tyr:
R?*® is Ala; and
Y? is amide, thioether, thioester or disulfide.
Unconventional amino acids which abbreviated in the formulae are as defined hereinbelow.
The currently most preferred backbone cyclized IL-6 antagonists of the invention which are derived from the IL-6& receptor molecule are as follows:
Trp-Arg-Lys- (D)Arg-Phe-AlaC3-Leu-Arg~ (D)Tyr-AlaN3-NH: designated herein as PTR-5045 (D)Lys-Arg- (D)Leu- (D)Arg- (D) Phe-AlaC3- (D) Leu~-Arg-(D) Tyr-AlaN3-
NH, designated herein as PTR-5041 (D) Phe-Arg~ (D)Leu- (D)Arg- (D) Phe-AlaC3-Leu- (D) Tyr-AlaN3-NH: designated herein as PTR-5043
These peptide analogs were found to inhibit the cytotoxic effect of IL-6 in various in-vitro bicassays. PTR 5045 was also found to be active in-vivo in prevention of IL-6 induced pathology, and to be metabolically functional bio-stable.
According to another aspect of the present invention, additional preferred analogs are derived from the sequence of the IL-6 molecule. According to the present invention the region of the IL-6 molecule spanning loop AB and helix D, is currently a most preferred embodiment for development of conformationally constrained backbone cyclized peptide analogs to be used as an inhibitor of IL-6 activity.
According to the present invention it is now disclosed that additional more preferred backbone cyclized analogs are hexapeptides antagonists of IL-6 with improved activity and metabolic stability. Additional more preferred analogs may advantageously include at least one D-isomer of amino acids in their sequence.
A preferred embodiment cf the present invention, relz+ting += regtices cerivTes Irom I1-%, nas the Icllowing foroiols:
R'--NR?----R3*---R%---NR’--R®-X {CH2) p—Y*~~ (CHz2) n
Formula No. 3 wherein m and n are 1 to 5;
X designates a terminal carboxy acid, amide or alcohol group;
R' is (D)Bip, Gln, Lys, Lys(ZCL) or Dab;
R? is (D)Lys, Gly, Rla or Trp
R® is Orn, 4PyrAla, (L) or (D)Dab, (D)Arg , Lys or Dpr:
R* is Lys, Lys(2CL), Arg, Arg(Mtr) or (D)Glu:
R® is Asn, Trp or (D)Ala;
R® is Arg, (p-NO2)Phe, (L)- or (D)- Trp, Gln, Abu or Glu; and
Y? is amide, thioether, thioester or disulfide.
Another preferred embodiment of the present invention, relating to peptides derived from IL-6, has the following formula:
NR'--NR®*--R’--R*--NR*--R®-X . m—Y2=— (CHz2) n 40
Formula No. 4 wherein m and n are 1 to 5;
X designates a terminal carboxy acid, amide or alcohol group;
R! is (D) Phe or Lys:
R? is (D)Git, Lys or (D)Bip;
R® is Dpr, 4PyrAla or (L)- or (D)- Arg;
R? is HomArg, Orn or Lys;
R® is (D)Gln or (L)- or (D)- Trp:
R® is (L)- or (D)- Gln or (p-NO2) Phe; and
Y? is amide, thioether, thioester or disulfide.
The currently most preferred backbone cyclized IL-6 antagonists of the invention which are derived from the IL-6 molecule are as follows: (D)Bip~ (D)LysC3-0Orn-Lys—-AsnN2-Arg-NH; denoted 70003-20; (D)Bip—-(D)LysC3-4PyrAla-Orn-TrpN2- (p-NO;) Phe-NH; denoted 70003-41; (D)Bip-(D)LysC2-Lys-Lys (2Cl)-(D) TrpN2-Abu-NH; denoted 70003-88;
Gln-GlyC2- (D) Dab-Arg (MTR) -TrpN2-Trp-NH, denoted 70003-61;
Lys {(ZCL)-GlyC2-Dab-(D)Glu-(D)AlaN3- (D) Trp—NH; denoted 70003-57; (D)Bip~GlyC2-Dab- (D)Glu-(D)AlaN3-Abu-NH; denoted 70003-391;
Lys (ZCL)-AlaC2-Dab-(D)Glu-(D)AlaN3-(D) Trp-NH> denoted 70003-25;
Lys-TrpC2=-(D)Arg-Lys-TrpN3-Gln-NHz denoted 70003-34;
Dab-TrpC2-Dpr-Arg(MTR)-(D)AlaN3-Glu-NH; denoted 70003-83; (D) PheC2~(D)Cit-Dpr-HomArg- (D)G1lnN2-(D)Gln-NH,; denoted 70003-17;
LysC3-Lys-4PyrAla-Orn-TrpN2- (p-NO2) Phe~-NH> denoted 70003-40;
LysC4-Lys- (D)Arg~Lys-TrpN3-Gln-NH; denoted 70003-33; {D) PheC2- (D)Bip-Arg-Lys- (D) TrpN2-G1ln-NH; denoted 70003-81.
Preferably, the backbone cyclized peptide analogs of the present invention incorporates two such N%g-functionalized amino acid derivatives which may be linked to one another to form N-backbone to N-backbone cyclic peptide analogs.
Additional preferred analogs of the invention can be constructed with two or more cyclizations, including N-backbone to N-backbone, as well as backbone to side-chain or any other peptide cyclization.
Backbone cyclized analogs of the present invention may be used as pharmaceutical compositions and in methods for the treatment of disorders including: cancers (including multiple myeloma/plasmacytoma), autoimmune diseases (including rheumatoid arthritis, multiple sclerosis, SLE and diabetes!, infectious diseases (bacterial and viral infection, septic shock), inflsmmatory diseases ‘Including pancrestisis, immo
Zefliciency diseases including RIZE), hemstslcooc Zissssas (e.g., Leukemia, _ymphcma., allergic diseases, crgan transplantation reactions, Castelman’s disease, Lennart’s
T-cell lymphoma, Non-Hodgkin’s lymphoma, Cardiac myxoma, mesangial proliferative glomerulonephritis, polyclonal B-cell activation conditions, abnormal acute phase protein production conditions.
The pharmaceutical compositions comprising pharmacologically active backbore cyclized IL-6 antagonist and a pharmaceutically acceptable carrier or diluent represent another embodiment of the invention, as do the methods for the treatment of a mammal in need thereof with a pharmaceutical composition comprising an effective amount of an IL-6 antagonist according to the invention. Methods of treatment using the compositions of the invention are useful for therapy of cancers (including multiple myeloma/plasmacytoma), autoimmune diseases (including rheumatoid arthritis, multiple sclerosis, SLE and diabetes), infectious diseases (bacterial and viral infection, septic shock), inflammatory diseases (including pancreatitis), immune deficiency diseases (including AIDS), hematologic diseases (e.g., plasma cell dyscrasias, leukemia, lymphoma), allergic diseases, organ transplantation reactions, Castelman’s disease,
Lennart’s T-cell lymphoma, Non-Hodgkin’s lymphoma, Cardiac myxoma, mesangial proliferative glomerulonephritis, polyclonal
: B-cell activation conditions, abnormal acute phase protein production conditions, and osteoporosis using such compositions. The pharmaceutical compositions according to the present invention advantageously comprise at least one backbone cyclized peptide analog which includes at least one D-isomer of amino acids in its sequence. These pharmaceutical compositions may be administered by any suitable route of administration, including topically or systemically. Preferred modes of administration include but are not limited to parenteral routes such as intravenous and intramuscular injections, as well as via nasal or oral ingestion. . BRIEF DESCRIPTION OF THE DRAWINGS
Figure 1 is a schematic drawing depicting known active IL-6 inhibitory and non-active peptides derived from the IL-6R.
Figure 2 describes the effect cf backbone cyclic peptide analogs on Bl6.F10.9 melanoma cells growth.
Figure 3 describes in-vivo effects of IL-6 antagonists on IL-6 mediated acute-phase responses: a) IL-6 serum levels, b) fibrinogen plasma levels and c¢) changes in body weight, in normal and IL-6 knockout mice.
Figure 4 is a chart describing the biological activity and selectivity of backbone cyclized peptide antagonists of IL-6, in TF1 cells maintained with IL-6 or GM-CSF.
The compounds herein described may have asymmetric centers.
All chiral, diastereomeric, and racemic forms are included in the present invention. Many geometric isomers of clefins and the like can also be present in the compounds described herein, and all such stable isomers are contemplated in the present invention.
By "stable compound" or "stable structure" is meant herein a compound that is sufficiently robust to survive isolation to a useful degree of purity from a reaction mixture, and formulation into an efficacious therapeutic agent.
As used herein and in the claims, the phrase "therapeutically effective amount” means that amount cf novel backbone cyclic certide znalcy or compositicn comprising sams to =iziris—er oo 2 Lcst tc achieve the desired results for toe Ioticscices described herein, such zs kut not limited cf Znflzmmsticn, cancer, endocrine disorders and gastrointestinal disorders.
The term, "substituted" as used herein, means that any one or more hydrogen atoms on the designated moiety is replaced with a selection from the indicated group, provided that the designated atom's normal valency is not exceeded, and that the substitution results in a stable compound.
When any variable {for example R, X, Z, etc.) occurs more than one time in any constituent or in any Formula herein, its definition on each occurrence is independent of its definition at every other occurrence. Also, combinations of substituents and/or variables are permissible only if such combinations result in stable compounds.
As used herein "peptide" indicates a sequence of amino acids linked by peptide bonds. The IL-6 peptide antagonists of this invention comprise a sequence of amino acids of 4 to 24 amino acid residues, preferably 6 to 16 residues, each residue being characterized by having an amino and a carboxy terminus.
A "building unit" indicates an N® derivatized « amino acid of the general Formula No. 5:
——————N~-CH (R’) -CO——
Formula No. 5 wherein X is a spacer group selected from the group consisting of alkylene, substituted alkylene, arylene, cycloalkylene and substituted cycloalkylene; R' is an amino acid side chain, optionally bound with a specific protecting group; and G is a functional group selected from the group consisting of amines, thiols, alcohols, carboxylic acids and esters, and alkyl halides; which is incorporated into the peptide sequence and subsequently selectively cyclized via the functional group G with one of the side chains of the amino acids in said peptide sequence or with another w-functionalized amino acid derivative.
The methodology for producing the building units is described in US Patent No. 5,883,283 and International Patent
Applications WO 95/33765 and WO 98/04583, both of which are expressly incorporated herein by reference thereto for further details of this methodology. The building units are abbreviated by the three letter code of the corresponding modified amino acid followed by the type of reactive group (N for amine, C for carboxyl), and an indication of the number of spacing methylene groups. For example, GlyC2 describes a modified Gly residue with a carboxyl reactive group and a two carbon methylene spacer, and PheN3 designates a modified phenylalanine group with an amino reactive group and a three carbon methylene spacer.
As used herein "backbone cyclic peptide” or “backbone cyclized 40 peptide” denotes an analog of a linear peptide which contains at least one building unit that has been liked to form a bridge via the alpha nitrogen of the peptide backbone to another building unit, or to another amino acid in the sequence.
As used herein a "PTR" number denotes a reference number assigned to a backbone cyclic peptide analog that is synthesized, purified and fully characterized (e.g., by HPLC,
MS, capillary electrophoresis, by amino acid analysis for peptide content and amino acid ratio determination).
As used herein and in the claims, in the formulae of the mcre preferred backbene cyclic peptide zanalegs, the superscrizt mmoers IZollowing the sminc =zifs reisr to thelr gozitIoo numbers In the native II-¢ r=csegzcr or In the I1-¢€ mplscouls.
Abbreviations:
Certain abbreviations are used herein to describe this invention and the manner of making and using it.
For instance, AcOH refers to acetic acid, Ada refers to adamantanacetyl, Adac refers to adamantanecarbonyl, Alloc refer to allyloxycarbonyl, AIDS refers to acquired immune deficiency syndrome, Boc refers to the t-butyloxycarbonyl radical, BOP refers to benzotriazol-l-yloxy-tris-(dimethylamino)phosphecnium hexafluorophosphate, BSA refers to bovine serum albumin, Cbz refers to the carbobenzyloxy radical, CNTF refers to ciliary neurotrophic factor, DCC refers to dicyclohexylcarbodiimide,
DCM refers to Dichloromethane, Dde refers to 1-(4,4-dimethyl2, 6-dioxocyclohex-1-ylidene-ethyl), DIEA refers to diisopropyl-ethyl amine, DMF refers to dimethyl formamide,
DPPA refers to diphenylphosphoryl azide, Dtc refers to 5,5-dimethylthiazolidine-4-carboxylic acid, EDT refers to ethanedithiol, ESI-MS refers to electrospray ionization mass spectrometry, Fmoc refers to the fluorenylmethoxycarbonyl radical, HBTU refers to l-hydroxybenztriazolyltetramethyl-uronium hexafluorophosphate,
HF refers to hydrofluoric acid, HOBT refers to 1-hydroxybenzotriazole, HPLC refers to high pressure liquid chromatography, IL-1 refers to interleukin-1, IL-6 refers to interleukin-6, IL-6R refers to interleukin-6 receptor, IL-11 refers to interleukin-11, KS refers to Kaposi's sarcoma, LC-MS refers to liquid chromatography mass spectrometry, LIF refers to leukocyte inhibitory factor, LIF-R refers to leukocyte inhibitory factor receptor, LPS refers to lipopolysacaride, mAb refers to monoclonal antibody, MMPs refers to Matrix
Metalloproteinases, MPS refers to multiple parallel synthesis,
MS refers to mass spectrometry, NMM refers to
N-methylmorpheline, NMP refers to l-methyl-2-pyrolidonone, OSM refers to oncostatin M, PyBOP refers to
Benzotriazole-l-yl-oxy-tris-pyrrolidino-phosphonium hexafluorophosphate, PyBrOP refers to Bromo~tris- pyrrolidino-phosphonium hexafluorophosphate, RA refers to
Rheumatoid arthritis, RP refers to reverse phase, SLE refers to system lupus ethrythematosus, TBTU refers to 2-(1lH-benzotriazole-1-yl)-1,1,3,3-tetramethylurcnium tetrafluoroborate, tBu refers to the tertiary butyl radical,
TFA refers to trifluoroacetic acid, TIS refers to : tri-isopropyl-silane.
The amino acids used in this invention are those which are available commercially or are available by routine synthetic methods. Certain residues may require special methods for incorporation into the peptide, and either sequential, divergent and convergent synthetic approaches to the peptide sequence are useful in this invention. Natural coded amino acids and their derivatives are represented by three-letter codes according to IUPAC conventions. When there is no indication, the L isomer was used. The D isomers are indicated by "D" before the residue abbreviation. List of Non-coded amino acids: Abu refers to 2Z2-aminobutyric acid, Aib refers to 2-amino-isobutyric acid, B-Ala refers to pB-Alanine, Bip refers to Beta-(4-biphenyl)-alanine, Cit referes to citruline, Dab refers to Diaminobutyric acid, Dpr refers to diaminopropionic acid, HomArg refers to homo arginine, Hcys refer to homocystein, Lys(ZCl) refers to Lys with g-amino group protected by benzyl chloride, 1Nal refers to l-naphthylalanine, 2Nal refers to 2-naphtylalanine, Nva refers to norvaline,, (p-Cl) Phe refers to para chloro Phenylalanine, (p-NH)Phe refers to para amino Phenylalanine, (p-F)Phe refers to para fluoro Phenylalanine, (p-NO:)Phe refers to para nitro
Phenylalanine, 4PyrAla refers to 4-Pyridylalanine, Thi refers to thienylalanine.
As described earlier, IL-6 plays a pivotal role in mediating immune responses, acute-phase reactions and hematopoiesis.
HIwsTEr. _T nas Deen shown fTIhzT Ths loss of II-£2 regul=ETico oo its cverexpressicn, may be involved Inn 2 number cof psthoclcoozsl conditions. Specifically, elevated IL-6 levels are detected = bacterial, parasite and viral infections, including HIV, as well as in chronic autoimmune disorders such as rheumatoid arthritis, systemic lupus erythematosus, psoriasis, and multiple sclerosis. In addition, IL-6 is implicated in the pathology of various neoplasms, such as multiple myeloma, leukemia, Kaposi's sarcoma, renal cell carcinoma and cardiac myxoma. In particular, IL-6 has been recognized as the major cytokine required fcr growth cf multiple myeloma tumors and is also possibly involved in the n tumor-associated toxicity in multiple myeloma patients.
It is expected that peptides which inhibit IL-6 function will have broad therapeutic utility in many mammalian diseases.
Therapeutic use of backbone cyclized IL-6 peptide antagonists of the present invention is expected to be beneficial in treating a variety of IL-6 associated diseases, many of which are currently treated with immunomodulators or immunosuppresants.
Such IL-6 associated diseases include: a) Multiple myeloma/plasmacytoma. b) Autoimmune diseased (including, but not limiting to, rheumatoid arthritis, multiple sclerosis, SLE and diabetes).
c) Infection diseases (bacterial and viral infection, septic shock) . d) Inflammatory diseases. e) Immune deficiency diseases, including AIDS. f) Hematologic, diseases (e.g., plasma cell dyscrasias, leukemia, lymphoma). g) Allergic diseases. h) Organ transplantation reactions. i) Castelman’s disease. j) Lennart’s T-cell lymphoma k) Non-Hodgkin’s lymphoma. 1) Cardiac myxoma. m) Mesangial proliferative glomerulonephritis. n) Polyclonal B-cell activation conditions. 0) Abnormal acute phase protein production conditions. p) Osteoporosis
By way of exemplification of the principles of the present invention, a search for inhibitory peptides was focused on the
IL-6R/gpl130 interface. This was followed by an investigation of the IL-6/IL-6R and the IL-6R/gpl30 interfaces. According to one presently preferred embodiment the search comprises mainly rational design and combinatorial libraries screening using multiple parallel synthesis (MPS) approaches.
The advantages of backbone cyclic peptides over existing and previously suggested therapies of multiple myeloma, are as follows:
The suggested IL-6 inhibitor 1s non-cytotoxic as compared with the currently utilized cytotoxic drugs. The effect of the IL-6 antagonist would be specific to multiple myeloma cells and a small subset of IL-6 dependent cells, where the other cytotoxic drugs are non-selective and kill all types of dividing cells in the body.
The suggested IL-6 antagonist is small and thus non-immunogenic by nature, as compared to the potentially immunogenic antibodies, antibody fragments and minibodies.
The suggested IL-6 antagonist could be modified to be orally bioavailable. It is unlikely that proteins (antibodies, fragments or minibodies) would be orally available.
Over 7400 individual backbone cyclized peptide analogs were synthesized in MPS format and tested by at least one type of bioassay for inhibition of IL-6 bioactivity.
The best peptides achieved at this screening stage, demonstrated an estimated ICs; arcund 1 pM. This represents LL: to 100 fold improvement of peptide analogs available as linear ceptides derived from the II-8Z molecule.
About SD peptide analszs (FTEs), cSncsen Ty =oTiTicy from oo-s
MPS syntheses, were synthesized In large scale, purified and fully characterized. These PTRs were tested for IL-6 inhibitory activity in at least one in-vitro bioassay.
From the above described massive screening of backbone cyclized peptide analogs in MPS and PTR format three peptides were unexpectedly found as particularly active. These backbone cyclized peptide analogs mimic the IL-6R inhibitory domain of residues 249-258, and the region in IL-6 which binds to the receptor. But unlike the previously described peptides derived from these domains, these novel backbone cyclized peptide analogs possess unique features which make them more suitable for use in pharmaceutical compositions for treatment of pathological conditions associated with elevated levels of
IL-6.
The preferred backbone cyclized IL-6 antagonists of the present invention are now described.
One embodiment has the following formula:
R249_R250_pR251_p252_p253_Np254_p255_p256_p257_nn258_y = (CHz) n=¥*~ (CHz) n J
Formula No. 1 wherein m and n are 1 to 5;
X designates a terminal carboxy acid, amide or alcohol group;
R**® is Trp, (L) or (D)Lys, (L) or (D) Tyr or (D)Phe; rR? is Arg;
R?! is (L) or (D)Leu or Lys:
R**? is (L) or (D)Arg;
R233 ig (D)- or (L)- Phe;
R**® is Ala;
R**®> is (D)- or (L)- Leu or is Lys:
R?*®® is absent or is (L) or (D) Arg;
R*7 is (L) or (D) Tyr;
R**® is Ala; and
Y? is amide, thioether, thioester or disulfide.
A currently more preferred embodiment has the following formula:
R249_R250_R251_R252_p253_\p254_R255_p256_p257_np258_y = (CHz) m=¥?= (CHz) 5 4
Formula No. 2 wherein m and n are 1 to 5; - X designates a terminal carboxy acid, amide or alcohol group;
R**? is Trp, (D)Lys or (D)Phe;
R*° is Arg;
R>! is Lys or (D)Leu;
R?%? ig (D)Arg:;
R*** is (D)- or (L)- Phe;
R** is Ala;
R?% is (D)- or (L)- Leu;
R*® is absent or is Arg;
R*7 is (D) Tyr;
R*® is Ala; and
Y? is amide, thioether, thioester or disulfide.
A most preferred compound according to this embodiment is denoted PTR 5045 wherein the residues are as follows:
R?*? is Trp;
R*® is Arg;
R*®! is Lys;
R®*? is (D)Arg:;
R?°? is Phe;
R**" is Ala;
R*°® is Leu; p28 ig Arc; 22% is nlz; and
Y? is amide.
Another preferred compound according to this embodiment is denoted PTR 5041 wherein the residues are as follows:
R**® is (D)Lys:
R**® is Arg;
R*®! is (D)Leu;
R*>? is (D)Arg;
R**? is (D) Phe;
R®* is Ala;
R**® is Leu;
R?® is Arg;
R* is (D) Tyr;
R**® is Ala; and
Y’ is amide.
Another preferred compound according to this embodiment is denoted PTR 5043 wherein the residues are as follows:
R**® is (D)Phe;
R*? is Arg;
R*®! is (D)Leu;
R*? is (D)Arg:
R*>® is (D)Phe;
R*® is Ala;
R?>® is Leu:
R**® is absent;
R*7 is (D) Tyr:
R®*® is Ala; and
Y? is amide.
Another preferred embodiment of the present invention, relating to peptides derived from IL-6, has the following formula: 10 .
I (CHz2) n 4
Formula No. 3 wherein m and n are 1 to 5;
X designates a terminal carboxy acid, amide or alcohol group;
R' is (D)Bip, Gln, Lys, Lys (2CL) or Dab;
R® is {D)Lys, Gly, Ala or Trp
R® is Orn, 4pPyrAla, (L) or (D)Dab, (D)Arg , Lys or Dpr;
R* is Lys, Lys(2CL), Arg, Arg(Mtr) or (D)Glu;
R®> is Asn, Trp or (D)Ala;
R® is Arg, (p—-NO2)Phe, (L)- or (D)- Trp, Gln, Abu or Glu; and
Y? is amide, thioether, thicester or disulfide.
Another preferred embodiment of the present invention, relating to peptides derived from IL-6, has the following formula:
A . (CHz) n=¥*—— (CHz) 5
Formula No. 4 wherein m and n are 1 to 5; 40 X designates a terminal carboxy acid, amide or alcohol group;
R! is {(D) Phe or Lys:
R? is (DYCit, Lys or (D)Bip:;
R® is Dpr, 4PyrAla or (L)- or (D)- Arg:
R? is HomArg, Orn or Lys;
R’> is (D)Gln or (L)- or (D)- Trp;
R® is (L)-,or (D)- Gln or (p-NOZ2)Phe; and
Y? is amide, thioether, thioester or disulfide.
The most preferred backbone cyclized IL-6 antagonists of the invention described in table 1:
Tzfle 1: The most preferred analogs cf the IomTsnsizo. "PTR 5045 _Ip-ATrs-_,S- _, AIC-Sn@-RAL3Li-_E&i-mII- o CoT-m_zli-n (D) Tyr-AlaN3-X
PTR 5043 |(D)Phe-Arg-(D)Leu- (D)Arg- (D) Phe-AlaC3-Leu- (D) Tyr-
A i) Le SU where X is -NH; or -OH and the bridging group extends between the two building units.
A more preferred embodiment of the invention incorporates two
N%@-functionalized amino acid derivatives which may be linked to one another to form N-backbone to N-backbone cyclic peptide analogs.
The most striking advantages of backbone cyclization are: 1) Cyclization of the peptide sequence is achieved without compromising any of the side chains of the peptide thereby decreasing the chances of sacrificing functional groups essential for biological recognition and function. 2) Optimization of the peptide conformation is achieved by allowing permutation of the bridge length, direction, and bond type (e.g., amide, disulfide, thioether, thioester, etc.) and position of the bond in the ring. 3) When applied to cyclization of linear peptides of known activity, the bridge can be designed in such a way as to minimize interaction with the active region of the peptide and its cognate receptor. This decreases the chances of the cyclization arm interfering with recognition and function, and also creates a site suitable for attachment of tags such as radicactive tracers, cytotoxic drugs, light capturing substances, or any other desired label.
Peptide analogs can be constructed with two or more cyclizations, including N-backbone to N-backbone, as well as backbone to side-chain or any other peptide cyclization.
The second cyclization, can be formed by incorporating at least one additional building unit into a peptide sequence and linking it to another building unit, to the amino acid side chain or to any of the peptide terminals. In addition the second cyclization can be a side-chain to side-chain (including di-sulfide bond), or a side-chain to terminal cyclization.
It has now unexpectedly been found that the backbone cyclized
IL-6 antagonists of the present invention which were identified by screening of individual backbone cyclized peptide analogs that were synthesized and assayed for inhibition of IL-6 activity, are 10-100 folds more active than the linear IL-6 inhibitory peptides previously described.
The backbone cyclic peptides of this invention are novel analogs which mimic the IL-6R inhibitory domain of residues
249-258. The amino acid sequence of the backbone cyclic analogs is based on what was identified as the most active inhibitory fragment of the IL-6R (Grube and Cochran, ibid). Additional analogs mimic a non-continuos region of the IL-6 molecule, comprising the,contact residue of IL-6 to its receptor. These analogs have an additional advantage of having molecular weights of around 1000 dalton.
The present innovative backbone cyclic analogs preferably include 5 to 20 amino acids with special amino acid modifications. Specificzczlly, zt leszs*t cre aminc =zid in ezor zmz_cz = 2 Z-lscmer zi the aminc zcit.
The special feature of the ncvel backbone cyclic peptide analogs is their metabolic stability as tested in vitro against degradation of the most aggressive enzyme mixture in the body (e.g., renal homogenate). PTR 5045 is stable under these conditions for up to 24 hours. The previously described peptide analogs derived from the IL-6R, and fragments of the native protein, are significantly less stable metabolically.
General method for synthesis, purification and characterization of backbone cyclic peptides.
Synthesis:
Resin: 1 g Rink amide or Tenta-gel resin, with loading of 0.2-0.7 mmol/gr.
Fmoc-deprotection performed with 7 mL of 20% piperidine in NMP.
Twice for 15 minutes following 5 washes with 10 ml NMP for 2 minutes with shaking.
Couplings: 1. Regular couplings (coupling to simple amino acids): with a solution containing 3 equivalents amino acid, 3 equivalents
PyBroP and 6 equivalents of DIEA in 7 ml NMP. For 0.5-2 hours with shaking. Coupling is monitored by ninhydrine test and repeated until the ninhydrine solution become yellow. 2. Coupling of His and Asn with a solution containing 5 equivalents DIC and 5 equivalents HOBT in 10 ml DMF.
3. Coupling to Gly building units: with a solution containing 3 equivalents amino acid, 3 equivalents PyBroP and 6 equivalents
DIEA in 7 ml NMP. Twice for 1-4 hours with shaking. 4. Coupling to building units which are not Gly: with a solution containing 5 equivalents amino acid, 1.5 equivalents triphosgene and 13 equivalents collidine in 15 ml dioxane or
THF. Twice for 0.5-2 hours at 50°C with shaking.
Removal of the Allyl and Alloc protecting groups of the building units performed with 1.5 equivalents per peptide of
Pd(PPhs3)4 in 30 ml DCM containing 5% acetic acid and 2.5% NMM.
For 1-4 hours with shaking.
Cyclization performed with a solution containing 3 equivalents
PyBOP and 6 equivalents DIEA in 7 ml NMP. For 0.5-2 hours with shaking. Cyclization is monitored by ninhydrine test and repeated if necessary.
Cleavage performed using 82%-95% TFA supplemented with scavengers: 1-15% H20, 1-5% TIS and 1-5% EDT.
Purification:
An individual purification method for each backbone cyclic peptide is developed on analytical HPLC to give the maximum isolation of the cyclic peptide from other crude components.
The analytical method is usually performed using a C-18 Vydac column 250X4.6 mm as the stationary phase and water/ACN containing 0.1% TFA mixture gradient.
The preparative method is designed by implying the analytical separation method on the 2” C-18 Vydac preparative method.
During the purification process, the peak containing the cyclic peptide is collected using a semi-automated fraction collector.
The collected fractions are injected to the analytical HPLC for purity check. The pure fractions are combined and lyophilized.
Characterization:
The combined pure lyophilized material is analyzed for purity by HPLC, MS and capillary electrophoresis and by amino acid analysis for peptide content and amino acid ratio determination.
General method for synthesis, purification and characterization and screening of backbone cyclic peptides in MPS format.
The MPS procedure is used as the routine peptide development procedure. Individual peptides, or groups of a few peptides, are synthesized in 96-wells microtiter plates equipped with filters that allow passage of solvent but not of solid phase matrix. A simple and efficient valve apparatus that enables simultaneous closing and opening of all the valves (produced by
Millipore) is used. The system utilizes an apprcach in which each well is equipped with a solvent permeable membrane at the
Lotion that does nicht =llcow passzcs of pariiczlzz zhovs = oczzsz-o- szze. Tne process 21.CWS Tne To Tlzce resin in othe wells, perform reacticn in sclvent, ani remcve the =clvent from zl the wells simultaneously by applying vacuum. These special plates, which are available in the standard 96 well format allow the parallel synthesis of 96 peptides simultaneously. The synthesis scale of the procedure is in the range of 1-5 pmole per well. Following purification by C18 reverse phase columns (SepPak purification), which is also carried in the standard 96 well format, the peptides are routinely dissolved in 1 ml of water to yield a theoretical crude concentration of 1-5 mM (depending on synthesis scale). Monitoring of chemical quality of the resulting peptides is performed by ESI-MS analysis.
Analysis of several plates prepared on different occasions by different operators indicated a general success rate of about 80% as judged by the presence of the desired peptide mass in the crude preparation. Further analysis of a peptides from MPS is carried out by LC-MS. The analysis revealed crude peptide quality similar to crude preparations of peptides synthesized individually in large scale. Different steps or the complete process are now performed automatically using automatic peptide synthesizers. Peptides are tested for bioactivity at a dilution of 1:40 (theoretical crude concentration of 125 uM) , or higher, which apparently eliminated most of the toxic effects and enabled routine biological testing of peptides.
Detailed procedure for synthesis in MPS format:
For capacity of 5 pymole 10 mg resin with a substitution of 0.5 mmol/gr is used.
Fmoc deprotection: To each well 100 pl of 20% piperidine in NMP are added. The reaction shacked for 15 min. The NMP is removed by suction.
Washing after Fmoc deprotection: the resin is washed by placing 150 pl NMP into each well followed by evacuation of the solution by vacuum. This process is repeated 4 times.
Coupling using PyBroP:
Well capacity: 5 pmol
Amount of amino acid per coupling per well: 26 pmol
Amino acid in NMP concentration: 650 mM
Amino acid volume used: 40 pl
PyBroP amount: 26 pmol
PyBroP concentration: 403 mg/ml
PyBroP volume used: 30 yl )
DIEA added: 10 pl
Total reaction volume: 80 pl
The amino acids are added to the pre-activation plate, then a fresh solution of PyBroP is distributed into this plate followed by addition of DIEA. The solution from this plate is transferred to the reaction plate and shacked for 1 hour. This coupling is repeated twice.
Coupling using Mukayama reagent:
Amino acid solution at 650 mM — 40 pl
Mukayama reagent at 111 mg/ml- 60 pl
Collidine added per well- 15 pl
The same procedure as for coupling with PyBroP. Reaction temperature 50°C, reaction time: first coupling 4h, second coupling 16h.
Allyl Alloc deprotection: this step is performed after completing the assembly, by addition of 180 pl solution of 1.5 g Pd(PPhs)s in 20 ml CHCl; containing 5% AcOH + 2.5% NMM.
Cyclization- this step is performed by addition of 100 pl solution of PyBoP in NMP + DIEA.
Cleavage of the peptide from the resin and SepPak purification:
After final Fmoc deprotection the resin is transferred into a deep well micrdtiter plate, to each well 300 pl of TFA solution containing 2.5% TIS, 2.5% H»0, 2.5% EDT are added. Removal of the TFA is performede by lyophilization. After cleavage the peptides are purified by SepPak.
Screening of IL-6 antagonists for biological activity.
In-vitro bioassays :
Screening for bicactivity cf pectential IL-6 inhibitory reptides was perZcrmed In vitro. Inhibiticn cf IL-¢ results In The ds=zto of IL-6 dependent cell lines such as the murine T1165 and B3, or the human TF1l and XG1l. Alternatively, inhibition of IL-6 can be monitored by following the IL-6 induced differentiation of
A375, B16.F10.9 and M1 cells which results in continued growth of the cells. Measuring IgG secretion by CESS cell line can also be used for monitoring IL-6 inhibitory activity.
Five types of in vitro bioassays for IL-6 inhibiticn using different murine and human cell lines were used in different stages cI the search, for screening of inhibitory peptides.
Bioassay using BY cells
B9 (murine myeloma) cells require IL-6 for growth. Inhibition of IL-6 results in cell death. The assay procedure was performed as described in Halimi et al. (ibid).
Bioassay using T1165 cells
T1165 (murine myeloma cells) require IL-6 for growth and die if
IL-6 is omitted or inhibited. The validity of the assay was demonstrated by inhibition of IL-6 bioactivity using rabbit
IL-6 antiserum.
Bioassay using B16.F10.9 melanoma cells
The F10.9 sub-line of Bl6é (murine melanoma) expresses gpl30 but not IL-6R. Addition of human IL-6 and human IL-6R, or a chimera of IL-6/IL-6R results in differentiation which is associated with growth arrest of the cells. Inhibition of IL-6 results in i WO 00/72864 PCT/IL00/00305 continued growth. Since the end point of this assay is cell growth rather than cell death, this assay system was used primarily in order to differentiate between suspected toxic effects observed on BY or T1165 cells, and true inhibition of
IL-6 activity.
The B16.F10.9 cell assay was routinely used as a confirmation assay for the T1165 or TFl assay which were the primary screening assays (at different stages of the search).
Evaluation of the results in this assay is possible using two methods. One method uses vital dyes for monitoring cell growth.
The second method comprises visual observation of the cell morphology and establishing a cut off point based on the following observations:
Cells which are not treated with IL-6 create a monolayer that covers almost all the surface area. Treatment with IL-6 causes growth arrest and a morphological change: the cells become very narrow and elongated as compared to the more spread out shape of the non-treated cells. Treatment of the cells with IL-6 and an inhibitory peptide apparently completely restores cell growth but does not completely restores the cell morphology.
Treatment of cells with IL-6 and a non-inhibitory peptide results in cells that appear to be very similar to the IL-6 treated cells. - Based on such observations, the results of the assay are reported as the last concentration of the peptide that cause almost complete inhibition of the effect of IL-6.
Bioassay using A375 cells
The A375 are human melanoma cells. IL-6 induces differentiation of A375 cells which is associated with growth arrest similar to the phenomenon observed with the B16F10.9 murine melanoma cells. Thus, inhibition of IL-6 results in continued growth of the cells which is easily quantifiable. In such case toxicity of peptides would register as a false negative rather than false positive. This conditions is preferable during screening process. Second, since these are human cells, the molecules involved in the bio-response, i.e. IL-6, IL-6R and gpl30 are all of human origin thus ensuring authenticity of the tested peptide bioactivity. Another advantage of the A375 cells is their ability to be induced by other cytokines that share the gpl30 signal transducer, i.e. leukemia inhibitory factor (LIF) and oncostatine M (OSM). As can be seen in table 2, LIF alone does not affect A375 cells, unless the respective receptor (LIF-R) is also added. Apparently the A375 line we use lacks
LIF-R. OSM is highly effective alone. The availability of this assay system, allows us to test, the specificity of our IL-6 inhibitory peptides vs. other cytokines of the family, in an array of assays all using a single cell line. Assay performance iz dzscribed In Savino et al. (lkid).
Table 2: InhibiIticn of ASTI Zy cytckines cther than I1-€ [Cytokine [Concentration (ng/ml) |5 Imhibition (relative to IL-6)*
Fe LS EL * The maximal (plateau) inhibitory activity of IL-6 on A375 cells was taken as 100%
The assay was validated using rabbit IL-6 antiserum which was used to inhibit the biocactivity of IL-6. Testing of crude peptide preparations, as well as high concentrations of purified peptides resulted in marked toxicity to the cells.
Further results indicated that the toxicity is dose dependent and decreases with increasing dilution of the crude peptide preparation, or at low concentration of the purified peptides.
It is therefore anticipated that the assay can be used for screening of analogs with nM activity. It can be also used for specifically screening for demonstration of peptide selectivity in the context of gpl30 related cytokines in order to differentiate between peptides that inhibit IL-6 alone and peptides that inhibit IL-6 and additional, gpl30 using cytokines.
Bioassay using TFl cells
TF1 cells (human erythroleukemia) cells require IL-6 for growth and thus inhibition of IL-6 bioactivity results in cell death, similar to T1165 cells. The origin of all relevant molecules is human.
The problem associated with toxicity (false positive results), could be overcome in the TFl based assay since these cells can be induced by additional cytokines which are unrelated to IL-6 (not using the gpl30 signal transducer). It is possible to induce the cells to grow with IL-6 and with additional cytokine e.g. GM-CSF. Specific inhibition of IL-6 bioactivity is therefore expected to register only in cells induced by IL-6 and not with GM-CSF. Validity of the use of TF1l cells and of the differential inhibition concept was demonstrated by the use of rabbit IL-6 antiserum. Only the IL-6 induced growth was inhibited by the antiserum. Assay procedure is based on the procedure described in Fourcin et al. (ibid). The amount of - viable cells at the end of the assay is determined by staining . the cells with WST reagent as well as by measuring thymidine - 20 corporation (°H-T) .
Inhibition of the IL-6 using peptides derived from the IL-6R or from gpl30, but not from the IL-6 itself could result in 3 inhibition of other cytokines that also utilize the gpl30 signal transduction system. In order to test the specificity of the peptide analogs in that respect, biocassays for the bioactivity of some of the other cytokines in the groups (i.e.
IL-11, CNTF, OSM), are performed.
In-vitro binding assays
Binding assays are intended to measure the direct effect of the peptide on formation of the IL-6 active hexamer. Unlike the bicassays, the use of this assay could clearly demonstrate the mode of activity of the tested peptides. A simple format for such assay would be as follows: IL-6, IL-6R and soluble gpl30 would be mixed in solution together with the test peptide.
Capture of the putative hexamer would be achieved by an anti-gpl30 antibody and detection of the bound complex would be achieved by antibody to either IL-6 or IL-6R. A separate assay performed in order to test the interference of the peptide in the IL-6/IL-6R interaction.
Assays of similar format are used for testing the inhibition specificity of the peptide to the IL-6 bioactive complex by replacing the IL-6-IL-6R complex with commercially available cytokines and receptors of the other cytokines known toc utilize the gpl30 signal transducer.
In-vivc Assays
The prime clinical target fcr the I1-€ antagonist Zz multizls myeloma. In-vivo model systems are performed in mice ircculazted with murine IL-6 dependent myeloma cell lines. Nude mice grafted with human multiple myeloma cells are also used.
Other in-vivo assays which are used for testing the inhibitory effects of the backbone cyclized IL-6 antagonists are:
IL-6 mediated acute-phase response, IL-6 mediated adjuvant arthritis, and pancreatitis induced by taurocholic acid as described in the following examples.
The skilled artisan will appreciate that the following examples are merely illustrative and serve as non limitative exemplification of the principles of the present invention and that many variations and modifications are possible within the scope of the currently claimed invention as defined by the claims which follow.
Example 1. Detailed synthesis of PTR 5045
Trp-Arg-Lys- (D) Arg-Phe~AlaC3-Leu-Arg- (D) Tyr-AlaN3-NH;
Two grams of Tenta-Gel resin (0.22 mmol/g), were swelled in NMP in a reaction vessel equipped with a sintered glass bottom and placed on a shaker. All the Fmoc protecting groups were removed by reaction with 20% piperidine in NMP (2 times 10 minutes, 10 ml each) followed by NMP wash (5 times two minutes, 15 ml each). Fmoc removal was monitored by ultraviolet absorption measurement at 290 nm. The couplings of the amino acids:
Fmoc-Arg(pmc) -QH, Fmoc-Leu-OH, Fmoc-(D)Arg{pmc)-0H,
Fmoc-Lys (Boc) -OH, Fmoc-Arg(pmc)-0OH, Fmoc-Trp (Boc)-OH were carried out with 4 eq (1.76 mmol) of the amino acid +PyBrop (4 equivalents, 1.76 mmol)+ DIEA (8 equivalents, 3.52 mmol) in NMP (10 ml) for 1.5 hour at room temperature. Reaction completion was monitored by the qualitative ninhydrin test (Kaiser test).
After each coupling, the peptide-resin was washed with NMP (5 times with 15 ml NMP, 2 minutes each). The coupling of
Fmoc- (D) Tyr {t-Bu)-OH to AlaN3 building unit was carried out by use of 4eq of amino acid + a mixture of TPTU and ToPPyU(4 eq, 1.76 mmol) in 10 ml NMP + 8 eq DIEA, double coupling: first coupling 2h, second coupling overnight. The coupling of
Fmoc-Phe-OH to AlaC3 building unit was carried out by the same : manner. Coupling completion was monitored by HPLC . The
Allyl/Aloc protecting groups were removed by reaction with
Pd (PPh3)s and acetic acid 5%, morpholine 2.5% in CHzCl:, under argon, for 2 hours at room temperature. The peptide resin was washed with CHCli3( 3 times, 5 min 30 ML each) followed by NMP.
Cyclization was carried out with PyBOP 3 equivalents, DIEA 6 equivalents, in NMP, at room temperature for 2h. Final Fmoc deprotection was carried out with 20% piperidine in NMP as above. The peptide resin was washed with CHCl; and dried under reduced pressure. The peptide was cleaved from the resin by reaction with TFA 94%, water 2.5%, EDT 2.5%, TIS 1%, at 0°C for 15 minutes and 2 hours at room temperature under argon. The mixture was filtered and the resin was washed with a small volume of TFA. The filtrate was placed in a rotary evaporator and all the volatile components were removed. An oily product was obtained. It was triturated with ether and the ether decanted, three times. A white powder was obtained. This crude product was dried. The weight of the crude product was 400 mg.
After purification by HPLC a single peak was obtained with 100% purity as detected by analytical HPLC and capillary electrophoresis. The expected mass of 1489.7 daltons was detected by mass spectroscopy.
Example 2: the .effect of backbone cyclic peptide analogs on
Bl6.F10.9 melanoma cells growth.
Peptides were added to B16.F10.9 melanoma cells in the presence of 200 ng/ml IL-6 and 125 ng/ml sIL-6R. Incubation for three days. (Peptide concentration was calculated for average molecular weight of 1500 Da. Sequence of control peptides: PTR 504%: Trp~Arg-lys-'DV'Arg-Phe-Al=C3-T=u-Zro-Tor—Slz"3-14-
FTR alsl: Zys-Elylz-leu-ITle-Zlo-lesu-The-Zl070-T-z-l--z-1T3-
The results descrired in figure IZ show that ITI IZI4f =n ITE 5041 fully block IL-6 activity at concentration of about 250 nM while PTR 5049 and PTR 4041 are not active.
Example 3: The in-vivo effect of IL-6 antagonists on IL-6 mediated acute-phase response.
The objective was to establish a simple first-line in-vivo model, for testing the activity of IL-6 inhibitors. The turpentine model was chosen based cn the principal role that
IL-6 plays in this inflammatory response.
Systemic and localized inflammation elicit a general reaction in the organism, known as the acute phase response, which includes fever, loss of body weight, hypoglycemia, and changes in the serum levels of several plasma proteins produced by the liver. IL-6 is an important mediator of the acute-phase reaction (see Heinrich et.al., Biochemistry J. 1 265:621, 1990 for a comprehensive review), together with IL-1 and TNF-q. It has been shown previously that sterile tissue damage caused by injection of turpentine induces an acute-phase reaction, and that IL-6 is an essential mediator of this response (Rokita et.al., Cytokine 5:454, 1993).
To confirm this role of IL-6 in this phenomenon we used
IL-6~-deficient mice generated by gene targeting (knock out).
Method and Results
IL-6 knock-out (-/-) and matched wild-type (C57/Black; CB) mice were used. Sterile tissue damage was induced by subcutaneous injection of turpentine, 0.1 ml, into both hind limbs. IL-6 was determined in the serum by ELISA (QuantikineM, R&D). For liver acute-phase proteins, Fibrinogen was determined in citrated plasma, by the calcium method.
IL-6 levels rose 7-fold following turpentine injection in normal, but not in IL-6 deficient mice (Figure 3a).
Fibrinogen levels rose 3- to 4-fold following turpentine injection in normal, but not in IL-6 deficient mice (Figure 3b).
Loss of body weight occurred following turpentine injection in normal, but not in IL-6 deficient mice (Figure 3c).
No changes in fibrinogen levels were detected 6 hours after ] turpentine injection. Elevated fibrinogen levels were observed at 12 hours post injection, and reach a maximal level by 24 hours post injection.
Conclusions
Our results confirm the previously published findings (Kozak et al., American J. Physiology 272:2 R621, 1997; Kopf et.al.,
Nature 368:339-342, 1994), which suggest that IL-6 is an essential mediator of the acute-phase response to turpentine.
The turpentine model can serve as a first-line in-vivo assay to determine the pharmacological efficacy of anti-IL-6 treatments.
PTR 5045 was tested in this model in compare to the non-relevant control peptide PTR 4041 (Lys-GlyC2-Leu-Ile-Gln-Leu-Phe-GlyN3-Lys-Lys~-NH;). The results are summarized in the following table 3:
Table 3: The in-vivo effect of PTR 5045 on IL-6 mediated acute-phase response.
I EL
Ten mice received 1 or 10 mg/kg of each peptide zanalcg. = PTR ZI4% reduces py abcut nal the 2ffect mediztez zy II-:Z zZz ccdy weight during acute inflammation. The Ziffsrencs ZsTwssn
PTR 5045 and the control peptide 1s significant alsc iI zaxkincg only the 1 mg/kg dose.
Example 4: IL-6 mediated adjuvant arthritis.
The objective was to establish an in-vivo model of rheumatoid arthritis (RA), for testing the activity of Interleukin-6 (IL-6) inhibitors. The adjuvant arthritis model was chosen because it has clinical and pathological similarities to RA in humans, and based on the putative role that IL-6 plays -n this inflammatory condition.
Rheumatoid arthritis is a chronic, multi-system autoimmune disease, mainly characterized by a persistent inflammatory synovitis, usually involving peripheral joints in a symmetric distribution. IL-6 has been implicated in RA, since increased levels were found in serum and synovial fluid of RA patients, and these levels were correlated with clinical parameters of inflammation (Miltenburg et al., British J. Rheumatology 30:186, 1991). Adjuvant induced arthritis in rats is used as a model for human RA because adjuvant arthritic animals develop the inflammatory and immunologic features which are observed in
RA patients. Furthermore, IL-6 levels are elevated in the serum of arthritic rats, and the levels correlate with inflammation,
and with the progress of the syndrome.
Method and Results
Genetically susceptible Lewis rats were used. The arthritis is induced by a single injection of complete Freund’s adjuvant (CFA), containing heat killed Mycobacterium Tuberculosis in oil (10 mg/ml). The animals were injected intradermally at the base of the tail. The arthritis developed two weeks after immunization, and involved the small joints of the extremities.
The rats were then subjected to a clinical scoring of the inflamed joints, and to a histo-pathological evaluation.
The rate of success in inducing arthritis is greater than 85%.
Female rats are more susceptible than males.
Inflammation of the synovium, formation of pannus, erosion of cartilage and bone were all observed histopathologically, confirming the clinical severity.
Dexamethasone treatment completely abolished the clinical signs of arthritis, and can therefore be used as a positive control in this model. Delivery of the dexamethason treatment was successfully achieved by employing osmotic mini-pumps, which could also be used for the continuous administration of peptides.
Conclusions
Our results confirm the previously published descriptions of this RA model (Stanescu et al., Arthritis and Rheumatism 30:779, 1987).
The adjuvant arthritis model can serve as a disease model to determine the pharmacological activity of anti-IL-6 treatments.
The testing is based on scoring of clinical parameters at the onset of the disease (day 12).
Example 5: Pancreatitis Induced by Taurocholic Acid.
The objective is to establish an in-vivo model of acute pancreatitis for testing the activity of IL-6 inhibitors. The taurocholic acid induced pancreatitis model has clinical and pathological similarities to severe necrotizing acute pancreatitis. in its severe form acute pancreatitis has clear systemic manifestations such as: circulatory failure, metabolic acidosis, ascites, hyperglycemia, hyperlipidemia, and ultimately a multisystem organ failure. IL-6 has been implicated in acute pancreatitis, since elevated serum levels were more predictive of disease severity or lethality as ie compared with C-reactive protein in patients with acute vancreatitis (leser et 2al., Gastrzenmterslicos 17I1:7EZ:3, 130
Taurccoriclic scifi ingcucsd panorestitois in Tats “= osssc == = mcdel for human pancreatitis because pancrez<itis animals develop the biochemical and pathological features which are observed in pancreatitis patients. Furthermore, IL-6 levels were elevated in the serum of pancreatitis rats.
Method and Results
Male Wistar rats were used. The pancreatitis was induced by the infiltration of 0.5 ml of 10% sodium taurocholate, into several sites of the pancreatic parenchyma with a 30G needle. A prcgressive detergent effects took place, which resulted in a diffuse pancreatic necrosis, and a high mortality rate. The measured parameters were serum levels of the pancreatic enzymes amylase and lipase, serum IL-6, and mortality. In addition, a histopathological evaluation of the pancreas was performed.
A mortality rate of 60-80% was found in the pancreatitis animals, with no mortality in the sham control group.
Severe hemorrhages and necrosis were evident in the pancreas, after taurocholate induction.
Fat necrosis throughout the peritoneal cavity, and marked intestinal dilation were found at 24 hours.
A significant elevation in serum IL-6 was observed at three hours, and reached its peak within 6 hours from the taurocholate injection.
A significant elevation of serum amylase was observed at two hours after pancreatitis induction.
Conclusions
Our results confirm the previously published findings, that
IL-6 is elevated in animal models of pancreatitis.
The taurocholate induced pancreatitis model can serve as a disease model to determine the pharmacological activity of anti-IL-6 treatments.
The testing is be based on measuring levels of pancreatic enzymes in the serum, mortality, and histopathological scoring.
Example 6: Synthesis and in vitro activity of further preferred backbone cyclized IL-6 antagonist PTRs.
Additional PTR analogs that were synthesized are listed in table 4, together with their respective chemical and biological data. Most of the peptides were synthesized during the initial phase of the research as part of the effort to discovery active peptides. The best ICso were observed using the B16F10.9 cell assay are around 10 p/ml for PTR-5005 and around 20 pg/ml for . PTR-5037. Of these two peptides, only PTR-5005 appears to be . 20 active on TF1l cells.
Table 4: Summary of synthesis and bioactivity of certain preferred PTRs.
T1165 inhibition| B16F10.9 inhibition Sequence (100 ug/ml) (100 ug/ml) (33 ug/ml) -GIn-Pro -GlyN2 5005 98 132 | 37 [rAmlerA Phe GC Ler Arg Tyr -GlyN2
C3-Arg 5009 8 24 NT GlyC3-Glu-Ser-Gin-Lys-GlyN3-Ala-Ala-
Gln-Leu 3011 ¢ 11 23 | NT |Tvr-Arg-Leu-lie-Phe-Glu~-GlvNI-Arg-Tor- : 1GivCE : 5013! 28 22 NT 'Tyr-Arg-Leu-Arg-Phe-Glu-GlyNC-Arg- Tor i-GlyC2 -GlyC2
N3-Phe -Arg-Gln 02) NS Arg AL -Arg-Gln -Arg-Gln -Arg-Gln -GlyN2 -GlyC2
C3-Arg
C3-Ar
C3-Arg 5037 NT NT Tyr-Arg-Leu-Arg-Phe-AlaC3-Leu-Arg-Tyr -AlaN3-Ala-Glu 5039 NT TE -AlaN3
NT - Not Tested
Certain preferred analogs are described in table 5 and table 6.
Table 5: Certain preferred backbone cyclic peptide analogs capable of inhibiting IL-6 derived from either IL-6, IL-6R or gpl30. 04 [LGR [l= [Glu [Arg _jser |Lys [Thr [Phe |The [Thr [frp 06 [TT-6F [Ala [oTyo2|D71Azg [Phe [Lys [bbe [Phe |D/LThE [GINS [/LTEp 08 |TL-GR [Als [Val [Pro [clu |GIyCZ|so [ser |GIyN2 Phe Tle 08 |IT=6% [Ala [val [pro [clu [olycz hsp [ser [GIyNZ [Tyr |e 00 |TLe% [lu [Gly [elycz [ser [ser [Phe [Tyr [GIyNZ [Val ser 22
The average activity of the peptides found following the above procedure is estimated to be over 100 yM as estimated from the results of the MPS experiments.
Table 6: Summary of activity of certain preferred analogs derived from the IL-6R. active at
Lys |Arg| Lys Arg | Phe | AlaC3 Lys (D)Arg | BTyr | AlaN3 2° 182 uM i 2.lyslArz Lys | (DIArg Pre [&l=2ZZ I L=u AYz Tr RIaRI = 22 UN {CI Lys|AT3| Lys Erg Sfe 1 Aiac3 | Let | BIg (C)Tyr, 1855. 25 |not active
Nl iil Ml Wl id NE GX
Nd ct cl dl Kd NN [2
BTyr is a mixture of DTyr and LTyr, and thus these wells contain 2 peptides each.
The results in table 6 demonstrate a general agreement between the results of both types of bioassays. Most of the peptides tested which were positive on TF1l cells, were also positive on
B16F10.9 cells.
The best peptide analogs obtained appear to inhibit the effect of IL-6 on B1l6F10.9 cells at theoretical crude concentrations below 12 uM, suggested ICso values close to 1 uM. Somewhat higher ICsp values are observed in the TF1 assay.
Example 7: Design, synthesis, screening and identification of additional preferred backbone cyclized analogs derived from the
IL-6 molecule. }
Based on the crystal structure of IL-6 and experiments that correlate specific point mutations and IL-6 biological activity, crucial contact points in loop AB and helix D of the
IL-6 molecule were determined (Xu et al. J. Mol. Biol., 268: 468, 1897, and Simpson et al. Protein Sci. 6:929, 1887 and: references cited there). CL
Applying the methods for identifying pharmacophore containing molecules from a virtual library (as disclosed in international patent application PCT IL/00/00218 (WO 00/65467)), a set of molecules that contained the pharmacophore and mimic the corresponding region of ; IL-6 protein were obtained. Those molecules were used for the design of combinatorial libraries of 10’ different backbone cyclic molecules.
The synthesis of one example of these libraries (ab0373) is described in the following scheme: :
Step NBU-1* “| AA-1 1 15° 20
Step AA-2 NBU-2 AA-3 2 15 11 - 10
Step | AA-4 AA-5 | AAG NBU-3 : 3 10 17 : 10 10
Step AA-7 AA-8 AA-9 AA-10 : 4 10 17 10 9 : : CBU-2¢ AA-12 7 : 12
Step AA-11 CBU-1 5 11 17 . Step CBU-3 AA-13 CBU-4 6 10 7 9
Wherein: 48
AMENDED SHEET 2002 10- 3 1
( ® NBU represents a building unit with amine reactive group ® The number in the second line of each step represent the number of individual amino acids coupled in each split arm. © CBU represents a building unit with carboxyl reactive group.
The libraries were screened for binding of soluble IL-6. The information obtained was used for synthesis of backbone cyclic peptides in MPS format. Analyses for biological activity were performed on the TFl human cell line.
Eighteen backbone cyclic peptides from the first MPS plate exhibit more then 45% inhibition at 1:10 dilution. Since the endpoint of the bioassay used is cell death, there is a need to check the specificity of the killing action, and to examine whether the cell death is due to inhibition of the IL-6 signaling pathway. The peptide analogs were therefore analyzed for their ability to induce non-specific cell death when the same cells were maintained with GM-CSF (instead of IL-6) as growth factor. The results of few of such activity and selectivity assays are summarized in Table 7 and Figure 4.
Some of the analogs exhibits non-specific inhibition (for example peptide 1,2 and 5 in table 7 and Figure 4) but some (i.e. peptide 34 and 41) were clearly specific to the IL-6 pathway.
Table 7. Activity and selectivity of selected backbone cyclized analogs as determined in TF1l cells bioassay.
InhibitionofILGactivity(%)
I vl 23
Number | a [ b [| IL-6 [GM-CSF] 1.6 | GM-CSF 2 juz loo | ua | 107 [ 14 [| 115 8 | 9 6 | 15 | 36 | 20 | 8 17 [so] 44 [ 67 | -23 [ 80 | -30 27 [55] -186 | 28 | -64 [| 7 | 86 34 [97] 108] 9 [| -27 | 106 | 3 40 [4] 72 | 43 | 45 | 61 | 63 41 | 96 [100 | 95 [ 25 | 101 | -13 60 [1 [ 2 | 11 | -93 | 33 [| -151 61 | 54] s8 | 8 | 4 [ 58 | 49 88 J 9 | 98 | 112 | 103 | 114 | 15 91 | 98 [106 | 123 | 45 | 113 [ 75 92 |-t8[ 152] 25 | 79 | 8 [ -103 # Anti IL-6R antibody in concentration of 1.35 ug/ml used as positive control in the assays.
Claims (1)
- THE CLAIMS What is claimed is:1. A backbone cyclized peptide analog having IL-6 antagonist activity, comprising a peptide sequence of five to twenty amino acids that incorporates at least one building unit, said building unit containing one nitrogen atom of the peptide backbone connected to a bridging group comprising an amide, thioether, thicester or disulfide, wherein the at least one building unit is connected via the bridging group to form a cyclic structure.2. The backbone cyclized analog of claim 1 wherein the peptide sequence comprises six to twelve amino acids.3. The backbone cyclized analog of claim 1 wherein the peptide sequence incorporates at least one D-isomer of an amino acid.4. The backbone cyclized analog of claim 1 wherein the peptide sequence incorporates at least two D-isomers of an amino acid.5. The backbone cyclized analog of claim 1 wherein the linear peptide sequence is derived from the IL-6 receptor.6. The backbone cyclized analog of claim 1 wherein the linear peptide sequence is derived from the IL-6 molecule.7. The backbone cyclized analog of claim 1 having the general formula 1: R249_R250_R251_p252_p253 \p254_p255_p2s 6_r257_ NR? _y ~ (CHz) n=¥*~ (CHz) 1 Formula No. 1 40 wherein m and n are 1 to 5; X designates a terminal carboxy acid, amide or alcohol group; R%**® is Trp, (L) or (D)Lys, (L) or (D) Tyr or (D)Phe; R*° is Arg; R?! is (L) or (D)Leu or Lys: R*®? is (L) or (D)Arg; R*®? is (D)- or (L)- Phe; R**! is Ala; R?*®* is (D)- or (L)- Leu or is Lys; R®*® is absent or is (L}) or (D) Arg; R*? is (L) or (D) Tyr; R**® is Ala; and Y? is amide, thioether, thicester or disulfide.8. The backbone cyclized analog of claim 7 wherein RY? is Trp, (L)- or (D)- Lys or (D)Phe; R*° is Arg; R®! is Lys or (D)Leu; R?*? is (D)Arg; R**? is (D)- or (L)- Phe; R** is Ala; R**> is (D)- or (L)- Leu; R*®% is absent or is Arg; R?%7 is (D) Tyr: R?*® is Ala; and Y’ is amide, thioether, thioester or disulfide.9. The backbone cyclized IL-6 antagonist of claim 8 having the formula: Trp-Arg-Lys- (D)Arg-Phe-AlaC3-Leu-Arg-(D) Tyr-AlaN3-NH,10. The backbone cyclized IL-6 antagonist of claim 8 having the formula: (D)Lys-Arg-(D)Leu-(D)Arg- (D) Phe-AlaC3- (D) Leu-Arg- (D) Tyr- AlaN3- NH11. The backbone cyclized IL-6 antagonist of claim 8 having the formula: {D) Phe~-Arg-(D) Leu- (D)Arg- (D) Phe-AlaC3~Leu- (D) Tyr-AlaN3-NH,12. The backbone cyclized analog of claim 1 having the general formula 3: R'-—~-NR?---R*--——R%-——-NR®°---RS-X (CHz}m=¥"== (CHp) 5 —4 Formula No. 3 wnerein m and n are 1 to =; X designates a terminal carbcxy acid, amide or alcool group; R' is (D)Bip, Gln, Lys, Lys(ZCL) or Dab: R® is (D)Lys, Gly, Ala or Trp R’ is Orn, 4PyrAla, (L) or (D)Dab, (D)Arg , Lys or Dpr; R? is Lys, Lys (ZCL), Arg, Arg(Mtr) or (D)Glu; R® is Asn, Trp or (D)Ala; R® is Arg, (p-NO2)Phe, (L)- or (D)- Trp, Gln, Abu or Glu; and Y? is amide, thioether, thioester or disulfide.13. The backbone cyclized analog of claim 1 having the general formula 4: NR'--R*-~-R’--R*--NR°---NR®-X I (CHz)n 4 Formula No. 4 wherein m and n are 1 to 5; X designates a terminal carboxy acid, amide or alcohol group: 40 R' is (D)Phe or Lys: R* is (D)Cit, Lys or (D)Bip;: R’ is Dpr, 4PyrAla or (L)- or (D)- Arg: R® is HomArg, Orn or Lys;R®> is (D)Gln or (L)- or (D)- Trp: R® is (L)- or (D)- Gln or (p-NO;)Phe; and Y? is amide, thioether, thioester or disulfide.14. A pharmaceutical composition comprising a backbone cyclized IL-6 antagonist comprising a peptide sequence of five to twenty amino acids that incorporates at least one building unit, said building unit containing one nitrogen atom of the peptide backbone connected to a bridging group comprising an amide, thioether, thicester or disulfide, wherein the at least one building unit is connected via the bridging group to form a cyclic structure, together with a pharmaceutically acceptable carrier or diluent.15. The pharmaceutical composition of claim 14 wherein the IL-6 antagonist is a backbone cyclized peptide analog having the general formula 1: R249_R250_R251_R252_p253_\p254_pR255_pR256_p257_\p256_y = (CHz) n=Y’= (CHz) 5 Formula No. 1 wherein m and n are 1 to 5; X designates a terminal carboxy acid, amide or alcohol group; R**® is Trp, (L) or (D)Lys, (L) or (D) Tyr or (D)Phe; R*® is Arg; R*®! is (L) or (D)Leu or Lys: R*** is (L) or (D)Arg; R®3 js (D)- or (L)~- Phe; R*** is Ala; R**® is (D)- or (L)- Leu or is Lys; R?*® is absent or is (L) or (D) Arg; R*®" is (L) or (D) Tyr; R**® is Ala; and Y? is amide, thioether, thioester or disulfide. 4016. The pharmaceutical composition of claim 15 wherein the IL-6 antagonist is a backbone cyclized peptide analog having the formula: Trp-Arg-Lys-(D)Arg-Phe~-AlaC3-Leu-Arg- (D) Tyr-AlaN3-NH,17. The pharmaceutical composition of claim 15 wherein the IL-6 antagonist is a backbone cyclized peptide analog having the formula: (D)Lys—-Arg- (D)Leu~(D)Arg-(D) Pre-AlaC3- (D) Leu-Arg- (D) Tyr- AZaN3- NH;23. The pharmaceutical zccmpositicon cf claim 1S wherer- Ths IL-t antagonist Is a Zackocne cyclized peptide anmalcs having the formula: (D) Phe-Arg- (D) Leu- (D) Arg- (D) Phe-AlaC3-Leu- (D) Tyr-AlaN3-NH,19. The pharmaceutical composition of claim 14 wherein the IL-6 antagonist is a backbone cyclized peptide analog having the general formula 3: R'----NR?---R3*----R*----NR®°---R®-X I (CHz)n ~ Formula No. 3 wherein m and n are 1 to 5; X designates a terminal carboxy acid, amide or alcohol group; R! is (D)Bip, Gln, Lys, Lys{ZCL) or Dab; R® is (D)Lys, Gly, Ala or Trp R? is Orn, 4PyrAla, (L) or (D)Dab, (D)Arg , Lys or Dpr: R' is Lys, Lys (2CL), Arg, Arg(Mtr) or (D)Glu; R®> is Asn, Trp or (D)Ala; R® is Arg, (p-NO2)Phe, (L)- or (D)- Trp, Gln, Abu or Glu; and Y? is amide, thioether, thioester or disulfide. 40 20. The pharmaceutical composition of claim 14 wherein the IL-6 antagonist is a backbone cyclized peptide analog iv] } . having the general formula 4: NR'<-R?---R’--R*--NR®*-~-NR®-X ; CT (CH2) w=Y*~= (CHz) n J : " Formula No. 4 =~ = wherein m and n are 1 to 5; : X designates a terminal carboxy acid, amide or alcohol group; Co : R' is (D) Phe or Lys; R’ is (D)Cit, Lys or (D)Bip; R® is Dpr, 4PyrAla or (L)=- or (D)- Arg; R' is HomArg, Orn or Lys; R> is (D)Gln or (L)- or (D)- Trp; TT. : R® is (L)- or (D)- Gln or (p-NO:)Phe; and Y? is amide, thioether, thioester or disulfide. ) 21. A pharmaceutical composition comprising a therapeutically effective amount of a backbone cyclized IL-6 antagonist for use in a method for treating disorders selected from the group consisting of neoplasms, bacterial, parasite and viral infections, chronic autoimmune disorders and osteoporosis.22. The composition of claim 21 wherein the IL-6 antagonist is a backbone cyclized peptide analog having the general formula 1: R219_R2S0_R2SI_R252_R283_\p254_pR2s5_p256_p257_\p258_y IY Formula No. 1 wherein m and n are 1 to 5; 40 X designates a terminal carboxy acid, amide or alcohol group; - R**® is Trp, (L) or (D)Lys, (L) or (D) Tyr or (D)Phe; R*® is Arg; 56 oo AMENDED SHEET 2002 -10- 3 1 i t R*! is {L) or (D)Leu or Lys; R**? is (L) or (D)Arg; R** is (D)- or (L)- Phe; : . R*® is ala; S R2S* is (D)- or (L)- Leu or is Lys; oo : ’ R**® is absent or is (L) or (D) Arg; : R*7 is (L) or (D) Tyr; : : R*® is Ala; and | : N Y? is amide, thioether, thioester or disulfide. 0 :23. The composition of claim 22 wherein the IL-6 antagonist is a backbone cyclized peptide analog having the formula: : : Trp-Arg-Lys- (D)Arg-Phe-AlaC3-Leu-Arg- (D) Tyr-AlaN3-NH,.24. The composition of claim 22 wherein the IL-6 antagonist is a backbone cyclized peptide analog having the formula: (D)Lys-Arg- (D)Leu- (D)Arg- (D) Phe-AlaC3- (D) Leu-Arg~ (D) Tyr- AlaN3-NH,,25. The composition of claim 22 wherein the IL-6 antagonist is a backbone cyclized peptide analog having the formula: (D) Phe-Arg~- (D) Leu- (D) Arg- (D) Phe-AlaC3~Leu- (D)Tyr-AlaN3-NH,. : 25 26. The composition of claim 21 wherein the IL-6 antagonist is a - backbone cyclized peptide analog having the general formula 3: : R'=---NR?~--R3%-——-Rf-=--NR*---R®-X (CHz) m~Y3== (CHz) pn Formula No. 3 ’ wherein m and n are 1 to 5; X designates a terminal carboxy acid, amide or alcohol group; R' is (D)Bip, Gln, Lys, Lys(2CL) or Dab; 40 R® is (D)Lys, Gly, Ala or Trp rR? is Orn, 4PyrAla, (L) or (D)Dab, (D)Arg , Lys or Dpr; 57 AMENDED SHEET 2002 -10- 31R* is Lys, Lys(2CL), Arg, Arg (Mtr) or (D)Glu:; : R®> is Asn, Trp or (D)Rla; R® is Arg, (p-NOz)Phe, (L)- or (D)- Trp, Gln, Abu or Glu: . and : S v? is amide, thioether, thioester or disulfide. :27. The composition of claim 21 wherein the IL-6 antagonist is a. backbone cyclized peptide analog having the general formula 4: i Lichen. : : : Formula No. 4 wherein m and n are 1 to 5; 200 x designates a terminal carboxy acid, amide or alcohol group; : R' is (D)Phe or Lys; : R? is (D)Cit, Lys or (D)Bip:; ) : R’ is Dpr, 4PyrAla or (L)- or (D)- Arg; R? is HomArg, Orn or Lys; : : R® is (D)Gln or (L)- or (D)- Trp; R® is (L)- or (D)- Gln or (p-NOz)Phe; and _ Y? is amide, thioether, thioester or disulfide. ,30 . : .28. The composition of claim 21 wherein the disorder is selected from the group consisting of rheumatoid arthritis, : multiple myeloma and osteoporosis.29. The use of a therapeutically effective amount of a backbone cyclized IL-6 antagonist in the manufacture of a medicament for use in a method for treating disorders selected from the group : consisting of neoplasms, bacterial, parasite and viral infections, chronic autoimmune disorders and Osteoporosis. 58 ” AMENDED SHEET ppp -10- 31
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IL13023899A IL130238A0 (en) | 1999-06-01 | 1999-06-01 | Conformationally constrained backbone cyclized interleukin-6 antagonists |
Publications (1)
Publication Number | Publication Date |
---|---|
ZA200109637B true ZA200109637B (en) | 2002-11-22 |
Family
ID=11072866
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ZA200109637A ZA200109637B (en) | 1999-06-01 | 2001-11-22 | Conformationally constrained backbone cyclized interleukin-6 antagonists. |
Country Status (8)
Country | Link |
---|---|
EP (1) | EP1187624A1 (en) |
JP (1) | JP2003500453A (en) |
AU (1) | AU770612B2 (en) |
CA (1) | CA2375657A1 (en) |
IL (1) | IL130238A0 (en) |
NZ (1) | NZ515493A (en) |
WO (1) | WO2000072864A1 (en) |
ZA (1) | ZA200109637B (en) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6841533B1 (en) | 1995-12-07 | 2005-01-11 | Peptor Limited | Conformationally constrained backbone cyclized interleukin-6 antagonists |
GB2401040A (en) | 2003-04-28 | 2004-11-03 | Chugai Pharmaceutical Co Ltd | Method for treating interleukin-6 related diseases |
JP2005060303A (en) * | 2003-08-12 | 2005-03-10 | Sutaagen:Kk | Agent for treating or preventing osteoporosis caused by immobility |
PT2592081T (en) * | 2010-07-06 | 2017-05-03 | Ono Pharmaceutical Co | Tetrahydrocarboline derivative |
ES2778053T3 (en) | 2011-01-18 | 2020-08-07 | Bioniz Llc | Compositions to modulate gamma-c cytokine activity |
US9959384B2 (en) | 2013-12-10 | 2018-05-01 | Bioniz, Llc | Methods of developing selective peptide antagonists |
CN108350032A (en) | 2015-10-09 | 2018-07-31 | 比奥尼斯有限责任公司 | Adjust γ C- cytokine activities |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5210075A (en) * | 1990-02-16 | 1993-05-11 | Tanabe Seiyaku Co., Ltd. | Interleukin 6 antagonist peptides |
JP3525221B2 (en) * | 1993-02-17 | 2004-05-10 | 味の素株式会社 | Immunosuppressants |
US5420109A (en) * | 1993-11-12 | 1995-05-30 | Houghten Pharmaceuticals, Inc. | Cytokine restraining agents |
WO1997048722A1 (en) * | 1996-06-20 | 1997-12-24 | The University Of Sheffield | Pyridine nucleotide-dependent enzymes |
-
1999
- 1999-06-01 IL IL13023899A patent/IL130238A0/en unknown
-
2000
- 2000-05-28 AU AU47763/00A patent/AU770612B2/en not_active Ceased
- 2000-05-28 EP EP00929763A patent/EP1187624A1/en not_active Withdrawn
- 2000-05-28 CA CA002375657A patent/CA2375657A1/en not_active Abandoned
- 2000-05-28 JP JP2000620973A patent/JP2003500453A/en active Pending
- 2000-05-28 WO PCT/IL2000/000305 patent/WO2000072864A1/en not_active Application Discontinuation
- 2000-05-28 NZ NZ515493A patent/NZ515493A/en unknown
-
2001
- 2001-11-22 ZA ZA200109637A patent/ZA200109637B/en unknown
Also Published As
Publication number | Publication date |
---|---|
AU770612B2 (en) | 2004-02-26 |
AU4776300A (en) | 2000-12-18 |
IL130238A0 (en) | 2000-06-01 |
WO2000072864A1 (en) | 2000-12-07 |
CA2375657A1 (en) | 2000-12-07 |
EP1187624A1 (en) | 2002-03-20 |
JP2003500453A (en) | 2003-01-07 |
NZ515493A (en) | 2003-07-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US5880096A (en) | Peptides and compounds that bind to the IL-1 receptor | |
US5767234A (en) | Peptides and compounds that bind to the IL-1 receptor | |
EP0246753B1 (en) | Fibroblast growth factor antagonists | |
US5210075A (en) | Interleukin 6 antagonist peptides | |
US5635597A (en) | Peptides that bind IL-2 receptors | |
US5677280A (en) | Peptides and compounds that bind to the IL-5 receptor | |
JP2514518B2 (en) | Somatostatin-like amide derivatives of heptapeptide and octapeptide, antitumor agent containing the same | |
US5106834A (en) | Linear free-sulfhydryl-containing oligopeptide derivatives as antihypertensive agents | |
CA2112907C (en) | Peptide which abrogates tnf and/or lps toxicity | |
US5614370A (en) | Assay to identify human C5a antagonists and agonists | |
AU737057B2 (en) | Cyclic CRF antagonist peptides | |
KR20230145543A (en) | High affinity cxcr4 selective binding conjugate and method for using the same | |
EP0833654A1 (en) | Peptides and compounds that bind to the il-1 receptor | |
AU770612B2 (en) | Conformationally constrained backbone cyclized interleukin-6 antagonists | |
US6323312B1 (en) | Cyclic CRF antagonist peptides | |
US6841533B1 (en) | Conformationally constrained backbone cyclized interleukin-6 antagonists | |
Simon et al. | Mapping of neutralizing epitopes and the receptor binding site of human interleukin 1 beta | |
KR20110093899A (en) | Tumor necrosis factor alpha inhibiting peptides and uses thereof | |
EP0700301A1 (en) | Peptides and compounds that bind to elam-1 | |
JP2003500334A (en) | RANTES-derived peptide having anti-HIV activity | |
RU2163242C2 (en) | Cyclohexapeptides, mixtures thereof, and method of preparing thereof | |
WO1995008560A1 (en) | Novel peptides useful for inhibiting binding of lipopolysaccharides (lps) by lipopolysaccharide binding protein (lbp) | |
US5011777A (en) | Vectors encoding brain derivable polypeptide factors | |
BG64386B1 (en) | New lh-rh antagonists with improved effectiveness | |
CA1328840C (en) | Fibroblast growth factor antagonists |